Medical Device ASIA, March-April 2016

HEART DISEASE!

Stress

About

WOMEN

MANAGEMENT!

STOMACHACHES!HighBloodPRESSURE

Treatment!

PreventionDiabetes

Program

Vol.8 No.2 | March-April 2016 | New Delhi

HKTDC HONG KONG INTERNATIONALMEDICAL DEVICES AND SUPPLIES FAIR

ShowReport!

MEDICALFAIR INDIA

Lose WeightLose WeightFASTER & SAFELY

A Checklist for Depression

Gove

rnm

ent o

f Ind

ia, Re

gistr

ar of

New

spap

ers o

f Ind

ia (R

NI)#:

DEL

ENG/

2009

/300

08

C

M

Y

CM

MY

CY

CMY

K

4047_MESSE_Medical Device Asia Ad_210x280Hmm_FAP.pdf 1 9/12/15 6:29 PM

Managing EditorSarvjit

Associate Editor &Public Relations Director

Reny

Joint EditorsVishwapreet

Amrita

ProductionRakesh

Marketing & CommunicationsLovleen

Web EditorRavindar

CirculationSurekha

Secretary & Legal AdvisorSurinder

China CorrespondentsYing Wei / Adrian Liu

The global healthcare mobility solutions market was evaluated atUS$20.19 billion in year 2014 and it is predicted to touch the revenueof US$110 billion US dollars by the end of year 2022.

Today, mobility has evolved as a main technology for healthcare sector, as ithelps the medical community to accept a patient centered approach,reducing healthcare expenses and the implications of the deficiency ofnursing as well as healthcare experts. Growing penetration of modernizednetwork techniques like personal digital assistants, smart phones and tabletsin healthcare services & systems combined with the emerging concentrationon patient centric mobility uses and applications is stimulating the growthand expansion of healthcare mobility solutions market globally.

Further, lack of skilled healthcare experts, high quality of healthcare services,best cost efficacy of mobility services, increased acceptance of mobilityservices by healthcare experts, shortage of nursing staff, and increasingmarket penetration of wireless network techniques like 3G and 4G arepredicted to propel the growth and expansion of the healthcare mobilitysolutions market universally. However, the privacy and data security issues

and interoperability threats related with the healthcare mobility services haslimited the broad acceptance of healthcare mobility solutions. Also short lifeof battery of mobiles & computers, lack of standardized protocols ofcommunication, fluctuating compensatory polices, price issues and issuesof infrastructure can pose a major threat to the growth and expansion of thehealthcare mobility solutions market worldwide.

The worldwide healthcare mobility solutions market was divided byproducts & services, by applications, by end users and by geographicallocations. The global healthcare mobility solutions market by products &services includes enterprise mobility podiums, mobile equipments andmobile applications. Mobile equipments comprises of barcode scanners,mobile computers, RFID scanners and others.

Key companies profiled in this market report includes McKesson Corpora-tion, Koninklijke Philips N.V., Airstrip Technologies Incorporation, OracleCorporation, Cisco Systems Incorporation, SAP SE, Cerner Corporation,AT&T Incorporation, Philips Healthcare, Zebra Technologies Corporation andOmron Corporation.

Global Healthcare Mobility SolutionsMarket 2016

4 HKTDC HONG KONG INTERNATIONAL MEDICAL DEVICESAND SUPPLIES FAIR

6 MEDICAL FAIR INDIA 2016 in Mumbai

14 Wound Healing 2016

16 The Pulmonary Arterial Hypertension (PAH) therapeuticsmarket

19 NAYATI MULTI-SUPER-SPECIALTY HOSPITAL

20 EOLIS air manager, 1st intelligent air filtration system to belaunched in India

23 Robotics Lasik Launched in Gurgaon

29 Aspirin Both Triggers And Treats An Often-Missed Disease

31 The smart way of providing affordable health care

35 9 Tips to Practice Yoga at Home

42 Diabetes Prevention Program under the Affordable Care Act isworking

50 How to Lose Weight Faster, But Safely

Medical Device ASIAMedical Device ASIAMedical Device ASIAMedical Device ASIAMedical Device ASIA | March-April 2016 | 33333

h i g h l i g h t s

Published, printed, & owned by World-Wide Publications at D-182, Anand

Vihar, Delhi-110092 and printed by him at Chandu Press, 63, Patparganj,

Delhi-110092. Editor: Sarvjit Kanwar

The publisher does not necessarily agree with the views expressed by the

contributors, in this issue, nor do accept any responsibility for any errors or

interpretation in the publication.

Vol.8 No.2 |March-April 2016 | Annual Subscription: India : Rs.2000 / Overseas: US$ 250

Medical Devices & Equipment | Healthcare | Pharmaceutical Journal

Editorial Advisory BoardAlex & Lilly - [email protected] McCourt - Australia

UK RepresentativeMike Steele, MJ Marketing20, Spencer Bridge RoadNorthampton NN5 5EZTel: +44-1604 756 100Fax: +44-1604-750 910

For advertising, subscribing or to submit a pressrelease, write to :D-182, PR House, Anand Vihar,New Delhi - India.Tel : +91 11 22141542 / 4309 4482Fax: +91 11 22160635Email: [email protected]

e d i t o r i a l

The 7th edition of the HKTDCHong Kong InternationalMedical Devices and Supplies

Fair will take place from 3 – 5 May,2016, at the Hong Kong Conven-tion and Exhibition Centre, withmore than 250 exhibitors from 11countries and regions participatingin this year’s fair.

The fair is divided into 15 specificproduct zones, including Rehabilita-tion and Elderly Care Zone, HospitalEquipment Zone, and TechExchange, showcasing latestremediation and therapeuticproducts. Nonetheless, the popularzone Physiotherapy Zone willdisplay the latest physiotherapyequipment, instruments and relatedservices and products, includingbraces, rollers, exercise parapherna-lia, sports equipment and more.

This year the pavilions include HongKong Medical & Healthcare DeviceIndustries Association Limited(HKMHDIA) Pavilion and ShenzhenAssociation of Medical Devices(SAMD) Pavilion, as well as the newparticipation of Pakistan Pavilion.Newly participating countries and

regions include Sweden, exhibitorsof which will bring along medicaldevices in the field of Otolaryngol-ogy; Vietnam will showcase a varietyof products, including diapers thatare specially designed for adults;Pakistan will present a wide range ofsurgical instruments, includingsections of the scalpel.

Institutional Medical Devicesand Supplies

Illies East Asia Limited fromHong Kong designs and developsits own AliveCor Mobile ECG whichis a "mobile electrocardiograph" thatlooks like a normal smart phonecase. As long as the application isinstalled in users’ compatiblesmartphone or tablet, users cankeep record of their electrocardio-gram and heart rate easily. The atrialfibrillation detector of this producthas passed FDA authentication.Healthcare Technology Interna-tional Limited’s Firefly WirelessMedical Camera Series includesOtoscope and Dermatoscope. Thesmall and lightweight cameras cancapture medical imaging or videoand instantly transmit to the

Present Leading-edge Products and Explore Medical Industry’s Advancements

HKTDC HONG KONG INTERNATIONALMEDICAL DEVICES AND SUPPLIES FAIR

computer for further use, like fordiagnostic and education purpose.It has been widely applied inotolaryngology, audiology,dermatology as well as veterinarydiagnosis, and is suitable for use inhospitals and clinics.

In addition, patients with backinjuries may need to use pillow assupport for fixing their body, orseek help from family members forturning side to side at midnight. JustMed Limited presents “SYSTAM30° Positioning Wedge”. Theergonomic stabilization supportercan maintain user’s body in 30°properly, which helps to minimizepressure from sacrum.

Doses of Insights with the LatestMarket Trends

Alongside a great array of innovativeproducts, the fair also presentsseminars and networking opportuni-ties. Different representatives wereinvited to the fair, including Nanoand Advanced Materials InstituteLimited, Hong Kong ProductivityCouncil and Hong Kong Scienceand Technology Parks Corporation,

to explain the latest technology andmarket trends in the medical andhealthcare device industry. Ir BryanSo, Executive Deputy SecretaryGeneral, Asian HarmonizationWorking Party will share his insightsinto the latest updates for medicaldevice regulations. The fair alsofeatures workshops and talks co-organized with Hong Kong DoctorsUnion and Hong Kong Health CareFederation respectively, so as toexchange information with industryplayers.

Organized by the Hong KongHospital Authority, the annualsignature event in the medicalindustry “Hospital AuthorityConvention 2016" will be heldconcurrently on the first two days ofthe Medical Fair in the same venue.Over 90 overseas and local speakerswill share their expertise andexperience with the industry.Besides, “Asia Biotech Invest”conference will also be heldconcurrently on the last day of thefair, providing biotech companies inthe Asia-Pacific region a platform forcooperation and exchanginginformation.

ILLIES EAST ASIA LIMITED(Hong Kong)Booth no.: 3G-B20Product Zone: Household Medical Products

JUST MED LIMITED(Hong Kong)Booth no.: 3G-A07Product Zone: Rehabilitation andElderly Care

HEALTHCARE TECHNOLOGYINTERNATIONAL LIMITED(Hong Kong)Booth No: 3F-G24Product Zone: HKMHDIA Pavilion

For more fair details, please visit:www.hktdc.com/hkmedicalfairEnquiries: [email protected]: (852) 1830 668

4 4 4 4 4 | March-April 2016 | Medical Device ASIAMedical Device ASIAMedical Device ASIAMedical Device ASIAMedical Device ASIA

Glo

bal S

olut

ions

for M

edic

al O

EMs

OEM

Co

mp

ress

ors

, Va

cu

um

an

d L

iqu

id P

um

ps

Oil-

Less

Op

era

tion

Mu

ltip

le P

um

pTe

ch

no

log

ies

Glo

ba

l Sa

les

&M

an

ufa

ctu

ring

Bro

ad

Ap

plic

atio

n

Ra

ng

e

Ga

rdne

r De

nve

r Eng

ine

ere

d P

rod

ucts

Ind

ia P

vt. L

td

305,

A-w

ing

215

Atr

ium

, An

dh

eri

– Ku

rla R

oa

d, C

ha

kala

, An

dh

eri

(E),

Mu

mb

ai –

400

093

. Te

l: +

91 (

022)

658

123

45 /

+91

(02

2) 6

1274

541

- 44

Indi

a: M

anoj

+

91 9

0042

8234

5

man

oj.a

hire

@ga

rdne

rden

ver.c

om |

SE A

sia: M

iche

lle

+ 8

52 9

170

0693

mic

helle

.wu@

gard

nerd

enve

r.com

Au

stra

lia: K

eri

+61

(0) 4

02 2

75 9

62

ker

i.mcn

eill@

gard

nerd

enve

r.com

| Ko

rea:

Eddi

e

+82

10

7720

258

4

edd

ie.le

e@ga

rdne

rden

ver.c

om

Japa

n: S

hiko

+8

1 90

805

1 53

94

shi

ko.iw

ai@

gard

nerd

enve

r.com

| Ch

ina: M

ark

+8

6-13

5-01

70-9

35

mar

k.lo

u@ga

rdne

rden

ver.c

om

MEDICAL TRADE FAIR REPORTSA 34% INCREASE IN VISITORS.

The MEDICAL FAIR INDIA 2016,India's No. 1 Trade Fair forHospitals, Health Centres and

Clinics, has continued its successfuldevelopment in the growth marketIndia in impressive fashion. Over10,700 professional visitors madetheir way to the Bombay Convention& Exhibition Centre in Mumbaiduring three intensive days of thetrade fair. This corresponds torecord growth of 34% compared tothe previous event in Mumbai.

The exhibitor figures also benefitedonce again from the strongeconomic situation in the industry:512 exhibitors from 16 countriespresented their product innovationsfrom the fields of medical technol-ogy and health management over anexhibition area of approx. 6,000square metres, and unanimouslypraised a successful trade fair.

All relevant Indian companies wererepresented in Mumbai, includingnumerous market leaders from Asia.298 exhibitors from other countriesbear witness to the growinginternationality of the event.

In addition to India, the largestexhibitor nations included China,Malaysia and Taiwan; Germany,France, Great Britain, Italy, Japan,Korea, Turkey, the UAE as well as theUSA also took part in the trade fair.On the initiative of the Spectaris andZVEI associations, Messe Düsseldorforganised an official joint companystand as part of the InternationalTrade Fair Programme of the FederalRepublic of Germany (AMP); thissignificantly facilitated participation inthe trade fair for exhibitors, andoffered both an optical as well as aprice benefit through an attractiveuniform image and favourable

MEDICAL FAIR INDIA 2016 in Mumbai:number of visitors exceeds expectations

conditions.

Horst Giesen, Global PortfolioDirector for the ̀ World of MEDICA´of the Messe Düsseldorf Group,gave a positive summary of the 22ndMEDICAL FAIR INDIA: "We did notexpect such a volume of visitors upto the last day of the trade fair. Thenew products, many of them fromthe high-tech sector, found a verypositive echo from professionalvisitors. Given extraordinary growthin the medical sector in one of themost populous countries in theworld, we also expect a strongtrade-fair business in future that canalso benefit our European exhibi-tors. MEDICAL FAIR INDIA and theglobally leading trade fair MEDICAcomplement each other".

The MEDICAL FAIR INDIA wasaccompanied by an extensivesupporting programme. A high-calibre professional conference withthe focal themes "HealthcareBranding, Marketing & BusinessDevelopment" as well as "InnovatingIndia with Healthcare Technology"offered decision makers from theclinic sector, medical professionals,dealers and players from industryand health management an idealforum at which to obtain informationon trends and to establish contacts.

Afzal Kamal, National Head of theleading professional journal formedical personnel in India, MedgateToday, again honoured particularlyoutstanding companies, hospitalsand medical professionals duringthe 22nd MEDICAL FAIR INDIA. Therenowned MT India HealthcareAward was presented to 32participating Indian companies andpersonalities from various catego-ries. For example, awards went tothe best doctors in Cardiac Surgery,Surgery, Gynaecology and Oncol-ogy, as well as to personnel from

the Healthcare sector (theHealthcare Personality of the Year),and to renowned companies suchas Hindustan Medical Devices,Ribbel International Ltd. or SpencerIndia Technologies Ltd.

Visitors to the trade fair includednumerous top decision makers fromhealthcare as well as renownedpersonalities such as Prof Dr Wali,Personal Doctor to the IndianPresident, Secretary General AnjanBose and Dr Jitendar Sharma,Director NHRC & Advisor to ChiefMinister Andrah Pradesh.

The next MEDICAL FAIR INDIA will beheld from 6 to 8 April 2017 in NewDelhi in line with the scheduledrotation.

The MEDICAL FAIR INDIA is part ofthe `World of MEDICA´ and is oneof the long-established internationalmedical trade fairs of the MesseDüsseldorf Group – organised inclose cooperation with the world'slargest medical trade fair MEDICA atthe Düsseldorf location.

Exhibitor Response to MEDICALFAIR INDIA 2016

Björn Kallmeyer, Managing director ofKallmeyer Medizintechnik GmbH &Co. KG (Germany): “For the first timeour local partner Easycare, pre-sented ERKA products. And withgreat success. With this we wereable to greatly improve our namerecognition in Mumbai und Delhi. Forfuture expansion we are looking foradditional local partners in otherregions of the large Indian market.”

Anand Singh, CEO of Thea TexHealthcare (India) Pvt. Ltd.: “Anexcellent show.

We have launched a new productand booked several orders. Very

professional expo. We were busyfor all three days. We will certainlybook for 2017!”

Anjali Gaur, Manager Sales &Marketing of Medico ElectrodesInternational Ltd.: “Medical Fair Indiahas always been a good experi-ence. Response was good. Surely,we would like to book a stand nextyear also.”

Devanshu Patel, Executive Director ofZeal Medical Pvt. Ltd.: “Proud to beassociated with Medical Fair Indiasince the very start. It’s always beenan upward graph and definitely willreach better heights.”

Satya S. Gupta, Director of GalaxyIndia: “We are thankful to MesseDüsseldorf India for giving us anexcellent platform and audience.The show was organised in aprofessional way with great services.We got the maximum targetaudience.”

Aditya Sarabhai, Managing Directorof AV Consumables: “Medical FairIndia is a great place to make newcontacts, meet up with existingclients and also one of the bestplaces to know the pulse of themedical industry.

Nikunj Kedia, Director of BellcrossIndustries: It’s a pleasure to beassociated with a reputable brand inexhibition industry. As a brandMesse Düsseldorf is such thatpeople fly from all over India toattend and participate in the MedicalFair India.For other exhibitions,Medical Fair India is the benchmarkof how to do it. Every year we getnew clients as well as newproducts.”

For more information, pleasecontact:http://www.medicalfair-india.com


Turkey pharma industry is among the primary industries that will makesignificant contribution to reaching the goals of our country for theyear 2023 with its deep-rooted history, long years of culture of

production, a structure based on high added value and advanced technol-ogy as well as experienced workforce and export potential. The Turkishpharma industry plays a significant role in the Turkish economy with over

to reducing current deficit. Turkeypharma market achieved 15.5%increase in economic value in 2016and reached 16.87 billion TL. 6.7%increase has been observed in thebox scale and production reached1.95 billion boxes.

Health spending per capita inTurkey is expected to reach2,000 dollars until 2023

Bringing together three socialsecurity systems implemented inTurkey under a single roof, theHealth Transformation Program hascompleted its 12th year. Followingthe program, hospital visits havealmost been multiplied by 3 timessince 2004 and this caused increasein pharmaceuticals usage. Accord-ingly, health spending in Turkey is

TURKEY PHARMA INDUSTRYONE OF THE PRIMARY INDUSTRIES IN THE GOALS OF THE COUNTRY FOR THE YEAR 2023Turkish and Global giant pharma companies come togetherunder one roof in CPhI Istanbul 2016...

The largest pharma exhibition in Eurasia, CPhI Istanbul 2016is preparing to welcome over 4,500 visitors from more than40 countries in Istanbul Congress Center between June 1stand 3rd. More than 200 exhibitors from over 25 countrieswill take part in the event where local and internationalpurchasing directors and suppliers will come together.

Moreover, the Turkey Pharma Industry Report which CPhIIstanbul initiated three years ago in order to shed light onthe industry and which it will organize with collaboration ofFortune Turkey Magazine this year will first be revealed inCPhI Istanbul 2016.

11,000 products, 65 manufacturingfacilities that make production inaccordance with internationalstandards, 11 raw material produc-tion facilities, over 300 institutionsand 30,000 employees. Having 13accredited R&D centers, the industrymakes export to 170 countries,particularly to USA, EU, Common-wealth of Independent States andMENA countries.

Turkish pharma industry's exportincreased by 9.8% in 2015 andreached 939 million US Dollars,whereas pharma import diminishedby 2.6% and reached 4.6 billion USDollars. This way the export / importcoverage ratio realized as 20.3%,reaching the highest in the 2010-2015 period and the pharmaindustry made positive contribution


expected to continue to grow by5.6% until the end of 2017. Thisgrowth rate exceeds the growth inthe largest health markets in theworld. Considering the changingdemographical structure, increase inthe frequency of occurrence inchronic diseases, continuedexpansion of health system in thecountry and works conducted formaking Turkey a center of medicaltourism, health spending per capitain Turkey is expected to increase by23.1% Compound Annual GrowthRate until 2023 and to be multipliedby three times, reaching 2,000dollars.

CPhI Istanbul 2016 quicklybecame the common and majormeeting point for the pharmaindustry in the Eurasia region

Having realized one of the mostprestigious meetings in the world,CPhI Istanbul is preparing to bringtogether the largest pharmacompanies in Eurasia for the 3rdtime on June 1st - 3rd. Creatingmajor opportunities for its exhibitorsand visitors in order to access thepharma industry in Turkey, MENA,Middle Asia and Caucasia, CPhIIstanbul 2016 has quickly becomethe common and major meetingpoint for the pharma industry in theregion.

Chief Operating Officer of Turkey inUBM EMEA (Istanbul), Haluk Balcisaid: "We organize 450 exhibitions ayear with over 5,500 employees in40 countries and we aim to improvethe exhibition business. We areequipping our experience andknowledge from the decades withcapabilities and facilities which noexhibition company can accomplishworldwide and we are using theseto serve the pharma industry and ourgeography. Accordingly, CPhIIstanbul was awarded the "BestTrade Fair Launch" award in theExcellence Awards of InternationalAssociation of Event Organizers

right at its first year."

Stating that Turkey owns 9.1 billiondollars market per year in the pharmaindustry alone and this is expectedto reach about 20 billion dollars in2023 with the investments to bemade, Chief Operating Officerof Turkey in UBM EMEA(Istanbul), Haluk Balci said:"About 400 million dollars' worth of33 investment projects are plannedfor establishing new and pharmaindustries and modernizing theexisting ones in the target markets.As UBM EMEA (Istanbul), weidentify our clients' needs beforethey do and we enable them toreach new markets constantly."

The firsts and innovations willappear in CPhI Istanbul 2016Pharma Exhibition

Mentioning that Turkey PharmaIndustry Report 2016 which isprepared with the collaboration ofFortune Turkey, one of the mostprestigious economy magazines inthe world will be announced in CPhIIstanbul 2016 for the first time, HalukBalci said: "Fingers are crossed forTurkey Pharma Industry Report 2016as the report keeps its finger on thepulse of the pharma industry andsteers its development. Our reportcontains findings regarding Turkey'spharma industry and data to guideand offer solutions for every kind ofneeds of local and foreign playerswho would like to take part in thislarge market."

CPhI Istanbul 2016 opens the gatesto its exhibitors and visitors for newmarkets by organizing meetingstitled 'Investment and BusinessOpportunities in the TargetCountries' in Turkey for the first timeand provides them with theprinciples and strategies applicablefor these markets. Stating that UBMEMEA (Istanbul) continues tochange the traditional order of theexhibition business model and

offers a special vision for itsexhibitors and visitors, Haluk Balcisaid: "We have designated thecountries that will take part in theworkshops we scheduled for thisyear with commissions of 3-4persons as Jordan, United ArabEmirates, Morocco, Israel, Iran,Lebanon, Saudi Arabia, Egypt,Algeria and Turkey. We will acceptour exhibitors and visitors to ourmeetings titled 'Investment andBusiness Opportunities in TargetCountries' to be held in the form ofhalf an hour sessions in groups of10 persons and we will providethem with strategic consultationservices, particularly on marketconditions."

Having the privilege of beingEurasia's largest pharma event, CPhIIstanbul 2016 addresses majortopics in the industry such asinvestment and business opportuni-ties, legal regulations and policies,production, R&D, new technologiesand supply chain and focusesfurther on new markets and thebusiness potential therein with aconference within the organization.It is expected that top levelexecutives from leading players ofthe countries in the region, scientistsand academicians from universitycommunities, senior representativesfrom state organizations andinstitutions, officials from industry-specific associations and founda-tions as well as investment experts,analysts and consultants will attendthe conferences as speakers andshare their opinions via case studyevaluations, panel discussions and

common presentations.Highlighted topics in the conferenceprogram are "Positioning Turkey asthe Global Pharma Production Centerby Building It On Entrepreneurship,Innovation and R&D Operations","Evaluation of Changing Dynamics inthe Market: How to Be StrongAgainst the Main Issues We AreFacing in the Pharma IndustryToday?", "Becoming Stronger in theMENA Region Using InvestmentStrategies and Effective Growth:Project and Portfolio Management","Middle East and North Africa as theHot Domain of the Large PharmaIndustry: New Production Facilitiesthat Rivet the Developing MarketStatus in the Region".

CPhI Istanbul 2016 is organized byUBM EMEA (Istanbul) with thesupport of the Turkish RepublicMinistry of Health, Turkish Drug andMedical Device Agency (TITCK) andSmall and Medium EnterprisesDevelopment Organization(KOSGEB) in official partnership withthe Pharmaceuticals ManufacturersAssociation of Turkey (IEIS). Also,DEVA Holding assumed thediamond sponsorship, Nobel Ilaçthe platinum sponsorship, HelbaIlaç, BD Medical Pharma andCCCMPHIE the gold sponsorship,Koçak Farma, Pharmactive, Vem Ilaçand Infa Group the silver sponsor-ship, Analitik Kimya, Mustafa Nevzat,Sanli Ilaç, BD Medical Pharma andInfoset, Harman Finochem, NoschLabs PVT, Pharma Action, Softi GelProcaps, Symbiotica and PromoPharma assumed the other sponsor-ships.

ABOUT UBM EMEA (ISTANBUL):

Headquartered in London, UBM is a London-listed global leading fairorganization business with offices in more than 40 countries and over5,500 employees. It is the world's second largest pure play eventorganizer. It is a member of the FTSE 250 index with over 450 events a year.In addition to traditional exhibition business, the company attaches greatimportance to technology and content and is a leading company thatensures each exhibition raises the bar in the industry each year.

For detailed information: ubmistanbul.com/tr/


STARLED7 NX is the operating lamp granting the best working conditions to surgeons and medical staff.

The new NX series of our STARLED lamps meets the highest quality standard requirements. STARLED7 NX produces a perfect IR-free light, with an excellent colour temperature and low consumption suitable for every situation. The Made in Italy design grants visual comfort, practicality of

use and compatibility with laminar flows. STARLED7 NX boasts an excellent light quality. The special optics of its LEDs, realized by ACEM, generates a shadowless, clear and homogeneous light assuring visual comfort and best working conditions both for the surgeon and for the medical staff.

Thanks to its next generation LEDs, the lamp can produce a perfect illumination under every condition generating a IR-free light, an excellent colour temperature and a practically endless life cycle at low consumptions. The lamp is composed by 57 next generation LEDs circularly placed and splitted into 7 reflectors (with 7 LEDs each one) and other 8 LEDs radially positioned around the handle.

STARLED7 NX produces a high illumination level of 160.000 lux. The colour rendering index of 95 and the colour temperature of 4.500 °K allow to reproduce the exact chromatic scale of the colours of the human body. The lamp is provided with ACRIS, the innovative system realized by ACEM that ensures, by the use of a microprocessor, the control of electrical curves typical of LEDs to remain unaltered over the time but maintaining a long life cycle (about 50.000 hours).

STARLED7 NX assures:• High quality illumination level for each kind of surgery• Colour temperature representing the contrast of the surgical area perfectly• Colour rendering index of 95 (CRI)• Clear luminosity at 160.000 lux• Colour temperature of 4.500 °K• Ergonomics for an extraordinary simplicity of use and easy positioning for the medical team• Exceptional duration with easier management and low consumptions

STARLED7 NX is provided with:• ACRIS, a smart system created by ACEM• A special system to adjust the light field dimension without mechanical parts through an optical-electronic management• A revolutionary I – SENSE® control system• An innovative LIGHT – UP system that, thanks to the special light beams coming from the upper part of the lamp, assures adjustable illumination levels according to the different use and particularlysuitable for minimal invasive surgery.

FOCUSED AND AMBIENT LIGHTIn order to achieve a correct illumination according to the different needs STARLED7 NX can produce a FOCUSED and AMBIENT light.Thanks to the special optics realized by ACEM, the light field focusing system adjusts the light spot diameter accurately assuring an excellent sharpness of details in the operating area. The light field dimension adjustment without

mechanical parts is possible through an optical-electronic management that grants a steady, homogeneous, shadowless and reliable illumination of the operating field in every situation particularly suitable for deep cavities.

AMBIENT light is managed by the LIGHT-UP system, a technology created by ACEM that produces adaptable and adjustable illumination levels according to the different uses thanks to the special light beams coming from the upper part of the lamp. This light allows to visualize the operating field as well as the surrounding environment clearly and is particularly suitable for minimal invasive surgery and for the preparation and treatment during the operation, monitoring of the patient and microscope operations.

Ergonomic, practical and functional designComfortable and light to move, thanks to its central handle, STARLED7 NX is practical also for the medical team who can move it from the lateral handles assuring stability and constant illumination even during the movement.STARLED7 NX has been manufactured with a smooth and resistant material that makes cleaning quick, easy and complete. On demand, the removable and sterilizable central handle can house a video camera shooting the surgical operations accurately (the video camera can be placed on a separate arm alternatively). The lamp shape assures visual comfort and is particularly suitable for laminar flows in the operating room.

The design is practical, functional and ergonomic. Thanks to AVSM system (Acem – Video – System – Management) STARLED7 NX is compatible with all the cameras and monitors offered by ACEM.

STARLED7 NX functions are managed by the handy, digital and easy-to-read I–SENSE® control panel positioned on the cardanic structure and adjusting:

• ON/OFF function• Light intensity• SIZE - Light spot diameter dimension (light beam focusing)• ENDO - Light for endoscopy• DOF - Depth of field – for a full visualization of the operating field and deep cavities• SYNC – (optional) Mode to synchronize controls among the combined lamps: STARLED7 NX double (twin dome configuration) and STARLED7 NX with STARLED5 NX or STARLED3 NX. The SYNC mode grants simplicity of use saving time and giving the possibility of being managed

by a single operator. The precise and easy-to-read I–SENSE® system is functional, simple and easy to clean.

The optional remote control is useful to manage all the functions of the lamp from a remote position offering the end-user better efficacy and practicity..

For more information: ACEM SpA, Medical Company Division, Via della Tecnica 29 - 40050 Argelato, Bologna – ITALY, Ph. +39 051 721844 Fax +39 051 721855, [email protected] www.acem.it

STARLED7 NX LED lamp for operating room

Medical Device ASIA | March-April 2016 | 9

In international clinical trials,PhytoRelief-CC’s patentedformulation has proven to be very

effective for conditions like cold andflu symptoms, upper respiratory tractinfections, and mucosal lesions ofthe mouth and throat

Alchem International launches thethird generation phytomedicinecalled PhytoRelief-CC to combatsymptoms of cough, cold and flu.

PhytoRelief-CC comes in the form ofchewable sugar-free lozengeswhich contain concentrated andpurified molecular extracts ofturmeric (haridra), ginger (zingiberofficinale), and pomegranate(dantabija). The synergistic effect ofthese nature-derived ingredientsoffers a host of benefits to quicklyand naturally cure symptoms ofcough, cold and flu. PhytoRelief-CChas very potent anti-viral, anti-bacterial, immune-modulatory, anti-inflammatory, anti-allergic and anti-oxidant properties. It has beendeveloped using AlchemLife’sproprietary Phytoplex™ technologybased on cutting-edge science todeliver unsurpassed efficacy withoutany side effects. Phytoplex™

technology is Alchem’s proprietaryextraction process which isolatesactive plant molecules in a way thatpreserves the ̀ natural balance’ and‘synergistic effects’ present in theoriginal plant material. Raman Mehta,Founder, Alchem International, said,“PhytoRelief-CC provides quick andeffective relief naturally, combiningthe power of traditional medicinalherbs with cutting-edge scienceand research. We expect a veryencouraging response as there ispresently no natural offering in themarket that is backed by clinicallyproven results for the preventionand treatment of symptoms of cold,cough and flu.”

In European clinical studiespublished in prestigious peer-reviewed international journals likeMinerva Gastroenterol Dietol andMinerva Medica, PhytoRelief-CC hasproven to be very effective forconditions like cold and flusymptoms, upper respiratory tractinfections, and mucosal lesions ofthe mouth and throat (associatedwith Bechet’s disease). Comparedto the placebo, PhytoRelief-CC ledto reduction of signs and symptomsof cold and flu within 2weeks, 83 %

reduction in bacterial load within 3days, and effective anti-viral activityagainst various strains of influenza.Tests have also shown significantimprovements in treating disordersof the mouth, throat and upperrespiratory tract infections within just4-5 days. Priced at Rs199 for a stripof 10 lozenges, PhytoRelief-CC willbe distributed in phases across thecountry at all retail and pharmacyoutlets.

Sudhir Mehra, Senior Vice President,Alchem International, said, “Theproduct will first be made availableacross North India and subse-quently register its presence in otherparts of India.”

About Alchem InternationalAlchem International develops andmarkets Third GenerationPhytomedicines – i.e.phytomedicines which undergointernational clinical trials for efficacyand safety - under the master brandAlchemLife. Third GenerationPhytomedicines are more efficaciousthan regular phytomedicines andhave no side effects because ofAlchem International’s proprietaryextraction Phytoplex™ Technology.

Third Generation Phytomedicineshave been developed by applyingmodern science to traditionalsystems of medicine from acrossthe world including Chinese,African, South American, Europeanand Indian. Third GenerationPhytomedicines are ideally suited forlong term treatment of ailments asthey have no side effects. They canbe used for primary therapy, or asadjuncts to primary therapy, thatdeliver long-term results with noside effects.Alchem International has over 75years of experience in manufacturingphytochemical-based ActivePharmaceutical Ingredients (APIs). Itsphytochemicals plant, the biggest inIndia, is certified by the US FDA,WHO-GMP and AFSSAPS (TheFrench Agency for the Safety ofHealth Products) and vendorvalidated by companies across theworld. 80% of its revenues aregenerated from global exports.The top selling Third GenerationPhytomedicine brands underAlchemLife include Liverubin (Livercare), Flexiqule (Joint care), MiraquleC 100 ( Cardio care), ProstaQuil(Prostate care) and PhytoRelief CC(Flu care).

ALCHEM INTERNATIONAL LAUNCHES THIRD GENERATIONPHYTOMEDICINE TO COMBAT COUGH, COLD AND FLU


The B-cell Non-Hodgkin’sLymphoma (NHL) treatmentmarket is set to rise slowly in

value from $4.38 billion in 2014 toreach $5.45 billion by 2024,representing a very modestCompound Annual Growth Rate(CAGR) of 1%, according toresearch and consulting firmGlobalData.

The company’s latest report* statesthat such limited growth, which willoccur across the seven majormarkets (7MM) of the US, France,Germany, Italy, Spain, the UK, andJapan, will be hindered by the entryof biosimilars and generics duringthe forecast period, combined witha weak pipeline.

Cai Xuan, Ph.D., GlobalData’s Analystcovering Oncology, says: “Thelaunch of biosimilar rituximab acrossthe 7MM in 2018 will have asignificant negative impact onbranded drug growth. Alsosignificant will be the impact thatgeneric bendamustine andlenalidomide will have on thetreatment space as they are released

at various intervals in each regionduring the forecast period.

“Furthermore, no late-stage drugs inthe NHL pipeline are expected toachieve blockbuster status, asrituximab-based chemotherapyregimens are gold-standardtherapies that dominate the NHLtreatment algorithms across bothindolent and aggressive forms of thedisease.”

The analyst adds that the high clinicalefficacy and established reputationof these immunochemotherapiesmakes developing a replacementtherapy in the first-line settingexceedingly difficult.

Xuan continues: “Despite this, thereis potential for some of the currentpipeline agents to be incorporatedinto the NHL treatment algorithmsacross indolent and aggressivelymphomas and in various lines oftherapy.

“For example, Roche’s Gazyva isbeing evaluated across the follicularlymphoma and diffuse large B-cell

lymphoma settings, while thedevelopers of Arzerra, copanlisib,and duvelisib are focusing onindolent NHL.”

GlobalData believes that while newplayers entering the NHL treatmentmarket must overcome variousobstacles, opportunities remainwithin this segment.

Xuan concludes: “The NHL market isin need of more cost-effectivetherapeutics, improved consolida-tion/maintenance therapies forfollicular NHL patients, and thedevelopment of novel drugs forNHL patients, all of which presentsignificant opportunities fordevelopment within this treatmentspace.”

*OpportunityAnalyzer: B-Cell Non-Hodgkin’s Lymphoma (NHL) –Opportunity Analysis and Forecaststo 2024

This report provides analysis of theNon-Hodgkin’s Lymphoma (NHL)treatment space across the sevenmajor countries of the US, France,Italy, Germany, Spain, the UK, andJapan, including annualized marketdata from 2014 and forecast to

B-CELL NON-HODGKIN’S LYMPHOMA TREATMENTMARKET WILL STUTTER TO $5.45 BILLION BY 2024• The Non-Hodgkin’s Lymphoma (NHL) market is forecast to experience only limited growth, rising from $4.38 billion in 2014 to $5.45 billion by 2024

• The NHL treatment arena will be prevented from experiencing any substantial growth by the entrance of biosimilars and generics through to 2024, saysanalyst

2024. It discusses market character-ization, unmet needs, opportunities,and research and developmentstrategies for the NHL market.This report was built using data andinformation sourced from propri-etary databases, primary andsecondary research, and in-houseanalysis conducted by GlobalData’steam of industry experts.For guidelines on how to citeGlobalData, please see: http://www.globaldata.com/QuotingGlobalData.aspx

ABOUT GLOBALDATAGlobalData is a leading globalresearch and consulting firm offeringadvanced analytics to help clientsmake better, more informeddecisions every day. Our researchand analysis is based on the expertknowledge of over 700 qualifiedbusiness analysts and 25,000interviews conducted with industryinsiders every year, enabling us tooffer the most relevant, reliable andactionable strategic businessintelligence available for a widerange of industries.

For more information, please contactour Press Office on +44 (0)161 3595822 or at [email protected].


Wound Healing 2016 runby Euroscicon Ltd wasan open forum event that

tackled the processes that areinvolved in wound healing. Theevent also discussed the relatedtherapies to wound infection andhealing. In addition to this, WoundHealing 2016 used an internationalsetting, inter-specialty and multi-professional approach that offershuge numbers of opportunities fordebate and discussion that is set inan informal atmosphere.

According to researchers at thisweek’s event, 40 million cases ofnon-healing chronic wounds areevident globally with ten millionreported in Europe alone. InEurope, wound managementaccounts for 2-4% of the healthcarebudgets. Aside from this, theproblematic biofilms in chronicwounds have been demonstratedto have a role to play in delayingwound healing and were alsoconsidered to increase the risk of awound developing an infection.

Dr Narendra Kumar, AssociateProfessor of pharmaceuticalsciences, at the Texas A&M IrmaLerma Rangel College of Pharmacy,USA, proposed to developed newways to completely protect andsecure the gut lining from wounds.But, available options for thetreatment of non-healing chronicwounds are limited when biofilmsare evident, as biofilms are inherentlyrecalcitrance to presently availableantimicrobial interventions. Biofilmsthat are present in chronic woundsrepresent a serious clinical issue for

the patient and a significant financialburden to health services world-wide. In conjunction with the needfor new antibiotics, as highlighted bythe Chief Medical Officer of CupronInc Professor Sally Davies, thedevelopment of innovative anti-biofilm agents is also urgentlyrequired.

According to Professor StevenPercival from The University ofLiverpool, “New research findingswere shared at Wound Healing2016, which will further advance ourfundamental understanding of thiscomplicated and dynamic process.”

The event also tackled that addingmicroscopic copper oxide particlesin wound dressings enhanceswound healing especially in hard toheal chronic wounds. The molecularmechanisms of the enhancedwound healing were also dis-cussed.

Wound Healing 2016: The Inaugural Eventheld at London, UK last January 26-28


Swissinnov Product a specialized firm in innovative pumpsystem recently launched a

pulseless dosing pump compatiblewith Masterflex L/S drives, the“NaoStedi”. This unique pumpserves multiple applications inpharmaceutical, medical, laboratory,chemical and industrial markets.

The “NaoStedi” pump deliversoutstanding performances in dosingaccuracy, flow control and is a newand fairly easy to use alternative totraditional peristaltic, diaphragm andsyringe pumps. “NaoStedi” pumphead can be sterilized andintegrated as OEM component inany devices using pump system.The “NaoStedi” pump functions withreciprocating pistons drivenindependently over the pumping

A new pulseless disposable pump runningon Masterflex L/S Drives has been launchedby Swissinnov Product

cycles to ensure a constant flowdelivery. The “NaoStedi” pumpdelivers pulseless flow without aneed for a calibration or flow sensor.

For an immediate evaluation of the“NaoStedi”, a starter Kit comprisingof a pump holder mounted in 5minutes on the Masterflex L/S drivesand 3 pump heads is availableonline at www.naopump.com.The Starter Kit is designed for acomprehensive testing of the“NaoStedi” on existing systemsrunning Masterflex L/S drives. Anyspecific requirements can bereviewed by Swissinnov Product.Swissinnov Product providesconsulting services for customdesigns and personalized solution.Swissinnov Product has long trackrecord in developing innovative

pumping system and solving complex fluidic problems. Its team of expertsworks constantly to provide new and unique pumping systems fordemanding applications.

Further information is available at: www.naopump.comSwissinnov Product sàrl, Rue Etraz 1, CH – 1196 GlandTel + 41 22 575 23 60 | Fax + 41 22 364 13 37


Despite Unmet Needs, PulmonaryArterial Hypertension TherapyMarket Will Hit $4.75 Billion by 2024,says GlobalData

The Pulmonary Arterial Hypertension(PAH) therapeutics market willexperience modest growth from$3.45 billion in 2014 to $4.75 billionby 2024, representing a CompoundAnnual Growth Rate (CAGR) of3.2%, according to research andconsulting firm GlobalData.The company’s latest report* statesthat the increase in PAH treatmentsales, which will occur across theseven major markets of the US,France, Germany, Italy, Spain, the UK,and Japan, will be driven by newdrug launches, the increased use ofdouble and triple combinationtherapies, and patient assistanceprograms by manufacturers.Lakshmi Dharmarajan, Ph.D.,GlobalData’s Senior Analyst coveringCardiovascular and MetabolicDisorders, says that despite thesedevelopments and growth in thePAH arena, significant unmet needswill remain by 2024, the most crucialof which is to find a cure for the fatal

disease.

Dharmarajan explains: “While thereare currently 12 marketed PAHtherapies available, they only serveto slow disease progression. Thereis no marketed drug that addressesthe underlying disease mechanismand targets to cure patients.“The main challenges in developingcurative or stabilizing therapiescome from a lack of understandingof the disease mechanism. This isnot helped by the fact that mostcompanies in the field are focusingtheir attention on reformulatingexisting PAH drugs and enhancingpatient convenience, rather thanimproving efficacy.”

The analyst adds that there is a greatneed to develop biomarkers andassays that could be used to predictpatient response upfront and maketreatment more personalized.However, there are no ongoingefforts to address this need in thePAH therapeutics market.In terms of what the PAH treatmentpipeline does have to offer, thereare only two drugs in late-stage

clinical development.

Dharmarajan continues: “The morepromising of the two late-stagepipeline PAH drugs is Actelion’sUptravi, a first-in-class prostacyclin IPreceptor agonist with a favorableclinical efficacy and safety profile.Uptravi was recently launched in theUS in January 2016 and is estimatedto be the highest revenue generatorof the PAH market at the end of theforecast period, recording near-blockbuster sales of $996 million in2024.

“The other Phase III candidate,Beraprost sodium 314d, does notdemonstrate as much potential dueto its lack of clinical superiority overother existing prostacyclin-basedtherapies.”

GlobalData believes that pharmaceu-tical companies should addressunmet needs by focusing theirattention on PAH-specific mecha-nisms which, although wrought witha high risk of failure, could potentiallylead to innovative and effectivedisease-modifying treatments.*OpportunityAnalyzer: PulmonaryArterial Hypertension – OpportunityAnalysis and Forecast to 2024

This report provides analysis of thePulmonary Arterial Hypertension(PAH) therapeutics space across the

The Pulmonary Arterial Hypertension (PAH)therapeutics market• Pulmonary arterial hypertension therapeutics market to rise gradually from $3.45 billion in 2014 to $4.75 billion by 2024, driven by new drug launches

• Growth will be modest due to the inability of new drugs to address underlying disease mechanisms, and the enduring search for a cure, says analyst

seven major countries of the US,France, Germany, Italy, Spain, the UK,and Japan, including annualizedmarket data from 2014 and forecastto 2024. It discusses marketcharacterization, unmet needs,clinical trial mapping and implicationsfor the PAH treatment arena.This report was built using data andinformation sourced from propri-etary databases, primary andsecondary research, and in-houseanalysis conducted by GlobalData’steam of industry experts.For guidelines on how to citeGlobalData, please see: http://www.globaldata.com/QuotingGlobalData.aspx

-ABOUT GLOBALDATA-GlobalData is a leading globalresearch and consulting firm offeringadvanced analytics to help clientsmake better, more informeddecisions every day. Our researchand analysis is based on the expertknowledge of over 700 qualifiedbusiness analysts and 25,000interviews conducted with industryinsiders every year, enabling us tooffer the most relevant, reliable andactionable strategic businessintelligence available for a widerange of industries.

For more information, please contactour Press Office on +44 (0)161 3595822 or at [email protected].


Zoetis, previously a subsidiaryof Pfizer, the largest animalhealth company in the world

has selected LemnaTec to providethe software and hardware for itslatest research into developingtreatments for parasites.

At its global R&D headquarters inKalamazoo, Michigan, Zoetisdevelops effective treatments for

internal and external parasites incompanion and production animalsby using in vitro models.

Senior Scientist Scott Timminscomments, “We were working withinternal parasites, using a 384 wellformat, checking by eye for areduction in motility.

This was hugely labour intensive andwe realised that itwould take manyyears to completethe programmewithout some kind ofautomation.”Following a visit tosee a LemnaTecmachine at BASF inGermany, we drewup a specification foran automatedphenotyping system

LemnaTec OS software screensparasites at Zoetis

that could use the 384 well formatwith backlight and dark fieldfunctionality. The machine, acustomized HTS Scanalyzer fittedwith a robotic arm to position theplates, was delivered by LemnaTecthe following year.

“We configured two cameras so wecould scan an entire 96 well platebut also individual wells in 96 and384 well plates”, says Scott. “Wealso introduced heat and carbondioxide to stimulate modelorganisms that would otherwise beimmotile is the absence of thestimulus.”

Having capacity for high throughputscreening that can deliver aquantitative output greatly increasesproductivity and accuracy whencompared to manual observationunder a microscope. One problem

the industry faces is that parasiteseventually become resistant toproducts. The Scanalyzer is used todetect which treatments areeffective against these resistantparasites.

“We use barcoded plates to trackcompounds and we record wellcoordinates plus the degree ofmovement of the sample. TheScanalyzer data is exported in CSVfile format to a statistics packagefrom which we analyse the data. Thisgives us a quick and easy way tointerpret results from one to manythousands of samples” concludesScott.The company provides a diverseportfolio of animal medicines andvaccines to meet the needs ofveterinarians, pet owners andlivestock farmers in more than 120countries.


The global market for peripheralvascular interventions, includinglower extremity stents,

percutaneous transluminalangioplasty (PTA) balloons, PTAdrug-eluting balloons (DEB), carotidstents, and renal stents, will rise from$2.1 billion in 2015 to $3.4 billion by2022, says research and consultingfirm GlobalData.

According to the company’s latestreport*, this expansion, which willoccur at a compound annualgrowth rate of 6.8%, will be drivenby an increased demand forminimally invasive endovascularprocedures, greater availability ofimproved solutions forfemoropopliteal arteryrevascularization, and the risingprevalence of peripheral arterydisease (PAD).

Premdharan Meyyan, GlobalData’sAnalyst covering Medical Devices,explains that the prevalence of PADis rising worldwide due to anincrease in risk factors such asdiabetes, hypertension, obesity,and tobacco use, resulting in agreater demand for minimallyinvasive treatments. An increasingnumber of physicians trained inendovascular techniques will help toaddress this.

Meyyan comments: “Drug-elutingdevices, including DEB and drug-eluting stents, are expected tosignificantly impact the treatmentparadigm of PAD during the forecastperiod, particularly for complexfemoropopliteal and infrapoplitealartery lesions where bare-metalstents and standard balloonangioplasty have not been aseffective as long-term treatments.

“The development of more efficientdrug delivery systems that maintaindrug concentration in the vessel wallfor longer periods of time will be asignificant market opportunity

moving forward, as this will improvelong-term efficacy.”

The current key players within thelarge and dynamic peripheralinterventions market are AbbottVascular, Boston Scientific, C.R. Bard,Cook Medical, Cordis, Medtronic,and W.L. Gore.

Meyyan continues: “Recent high-profile acquisitions, such asMedtronic’s acquisition of Covidienand Cardinal Health’s acquisition ofCordis, will significantly impact thecompetitive landscape movingforward.“Companies such as Biotronik, B.Braun, Maquet, and Eurocor are alsostrong potential competitors whichare poised for growth due toinvestment in innovative technolo-gies within this space, including DEBand polytetrafluoroethylene (PTFE)-covered stents.”

Peripheral Vascular Interventions Market WillClimb to $3.4 Billion by 2022


This World Kidney Day, NayatiHealthcare announced thecommencement of full

services at the cenre for RenalSciences (Nephrology & Urology).This new-age centre is a first-of-itskind in the region providingcomprehensive kidney care to thepatients through a full range ofdiagnostic, management andoperative services.

Niira Radia, Chairperson, NayatiHealthcare said “The Centre hasbrought together the finest medicalprofessionals, state-of-the-artinfrastructure and the higheststandards of clinical excellence andpatient safety. Our commitment is toget care to the patients doorstepand thereby reduce the social,emotional and economic burden oftreatment and this is yet another stepin that direction.” Dr. R K Mani, CEOMedical, Nayati Healthcare stated

“The burden of kidney relateddiseases is very high in all states ofIndia and equally if not more in UttarPradesh. Kidney disease is termed as“silent” disease because it is oftenunnoticed by most as few specificsymptoms appear in the beginningbefore it gets diagnosed. Hencedetection is at a late stage, compro-mising the outcomes. In WesternUttar Pradesh, there is a gaping lackof infrastructure and expertise intreating kidney disease. Till nowpatients have had to travel to DelhiNCR or other big cities for thepurpose. Now patients do nothave to travel long distance forevaluation, diagnosis, treatment ordialysis. The Centre will work as acohesive team with interdisciplinaryinteractions between nephrologists,urologists, critical care specialists,cardiac science specialists,oncologists and others.Dr. Krishna Sahu, Director & Head of

the Department of Nephrology &Kidney Transplant stated “Our centreis well equipped to treat patientswith acute and chronic kidneyfailure, hemodialysis and peritonealdialysis, kidney transplant, nephroticand nephritic syndrome, kidney andbladder stone, prostate and urinaryincontinence and kidney cancerpatients among others. It alsoinvolves comprehensive care forkidney diseases associated withother illnesses and conditions, suchas diabetes and hypertension. Wehave dialysis facility and we willstarting kidney transplant surgeriessoon. At Nayati, we are committedto provide precise & timely medicaltreatment to the people of theregion at affordable costs.”

The state of art dialysis unit will caterto routine as well as special dialysisfor very sick patients. The dialysisunit is supported by the latest water

Right to Left- Dr. Krishna MohanSahu(Director, Nephrology & KidneyTransplant) & Dr. Tapan Agrawal,(Associate Consultant, Urology) atNayati Hospital, Mathura

NAYATI MULTI-SUPER-SPECIALTY HOSPITAL MATHURAANNOUNCES COMMENCEMENT OF SERVICES AT THE CENTRE FORRENAL SCIENCES (NEPHROLOGY & UROLOGY)Comprehensive kidney care through a full range of diagnostic, management and operative services

Dialysis services commences from March 14

processing plant to produce ultra -pure water for safe and smoothdialysis of the patients. For specialdialysis of critically ill patients in ICU,the centre is equipped with latestgeneration SLED and CRRT machines.The unit is also supported by worldclass operation theaters to take careof all kinds of kidney & urologyrelated surgeries.

About Nayati Healthcare & ResearchPvt. Ltd., taking treatment to thepatient: Nayati Healthcare &Research is India’s first Multi Super-Specialty healthcare organisationoffering premium tertiary care to Tier-II & Tier-III cities. It offers world classpatient care services aided by state-of-the-art medical technology andadvanced treatment facilities. Theaim of the organisation is to providecost effective and easily accessiblehealthcare.

About Nayati Multi Super SpecialtyHospital, Mathura: Nayati Multi SuperSpecialty Hospital, Mathura onceoperational will be the first hospitalin the region to provide integrated,comprehensive and high qualityhealthcare through our Centres ofExcellence. These centres will besupported by advanced IntensiveCare units comprising of: MICU,CCU, SICU, NICU and PICU.

The upcoming hospital in Mathurawill also cater to Vrindavan, Agra,Palwal, Firozabad, Mainpuri, Kasganj,Etawah, Etah, Hathras, Agra andsurrounding areas.


NatéoSanté, a Frenchcompany specialising in airquality treatment, is about to

launch EOLIS, the first intelligent airfiltration system especially con-ceived for the Indian market.Manufactured in France, EOLIS isintended to be made in India laterthis year, at EOLANE industrial plantin Bangalore. EOLIS will be on sale inIndia from May 2016 and distributedthought our Indian Partners.

EOLIS air manager has beenconceived from the initial idea toprovide an air filtration systemcombining high performances andsimplicity of use. Tailored forprofessionals in home appliances,hospitality and heath/medicalsectors, EOLIS will incorporate a filtersystem composed of a medicalgrade filter HEPA H13 or ULPA U15and a high density active carbonfilter able to treat an area of either 60or 120 m² (two versions will beproposed). Nateosanté air filtrationsystems are equipped with the mostefficient filters on the market. Inorder to ensure 99.9% purification,our units are silent, reliable, easy touse, adapted to your needs andenergy efficient. Natéosanté is very

successful in Asia, with severaltrusted references (Renault, PSA,Mutualité Française, Miele …).

The Indian market is extremelypromising as declared by Mr.Stéphane Monnier, InternationalBusiness Development Manager:“India is a strategic market for ourcompany and we want to provideIndian professionals with the bestequipment to treat air pollution.Some of the cities in India like NewDelhi are facing huge challenges dueto very heavy levels of concentrationof fine and ultrafine particles in theair, and NateoSante wants to workwith Indianprofessionalswith productslike EOLIS thathave a proventrack record forimprovingquality of airand quality oflife.”

EOLIS is morean AIRMANAGERthan an AirPurifier.

Thanks to the ACTIV mode, EOLIS isa smart unit automatically adapted toyour environment. It includes amonitoring system easy to usethanks to a three user controlinterface: touch screen panel,computer or smartphone. Becauseeach product is unique and get aspecific ID number, we can see howit works and when you needmaintenance and filters to bereplaced.

EOLIS air manager will be available inIndia from May 2016 and distributedthought our Indian Partners.Available in two versions dependingon the area surface to be treated (60or 120m²), it is the first intelligent airfiltration system to be marked withCE certifications.

About NATEOSANTE:NatéoSanté is a French companycreated 7 years ago and specialisingin quality of indoor air. The companyhas already provided thousands offamilies and professionals in Franceand in Asia. Our product line hasbeen built and improved day afterday, through concrete feedbackfrom our customers, enabling us tobecome a reference on the market.Our experts know the problemswhich may be faced by ourcustomers, we work every day tooffer them solutions by taking fullaccount of the specificities of each

EOLIS air manager, 1st intelligent air filtra-tion system to be launched in India

environment.

For further information, please visit:http://www.nateosante-pro.fr/

About Business France:Business France is the nationalagency supporting the internationaldevelopment of the Frencheconomy, responsible for fosteringexport growth by French busi-nesses, as well as promoting andfacilitating international investment inFrance. It promotes France’scompanies, business image andnationwide attractiveness as aninvestment location, and also runsthe V.I.E international internshipprogram. Business France has 1,500personnel, both in France and in 70countries throughout the world,who work with a network of public-and private-sector partners. Forfurther information, please visit:www.businessfrance.fr andyoubuyfrance.com.in.

Company contact:Mr. Stéphane MONNIERNATEOSANTEInternational Business DevelopmentManagerTel: (+33) 2 85 52 06 75 / @:[email protected]

Press contact:Mr. Thomas ILHEBusiness France, French Trade


Gainsborough-basedEminox, a leader in themanufacturer of exhaust

after-treatment technology for heavyduty diesel vehicles, and CalanEnvironmental Technology, aspecialist automotive distributor,have signed a distribution ventureagreement to supply DieselParticulate Filter solutions in China.

The cooperation will involve Eminoxproviding its market-leading DieselParticulate Filter (DPF) technologies,which have been developed andrefined over the last 20 years. TheDPF range, including CRT® andFBC®, have shown in real worldtests to reduce particulate matter byboth mass and number, includingultra-fine particles that are mostdamaging to health.

“The signing of the agreement byNick Lyons, Deputy ManagingDirector of Eminox and ZhaohanDing, CEO of Calan Environmental

Technology, coincided with therecent “UK-China Leadership Forum”attended by All Party ParliamentaryChina Group Chairman RichardGraham MP.”

Air pollution is a major environmentalchallenge in China; in order to curbemissions an increasing number ofprovinces are introducing retrofitschemes. These tough, newemission standards have alreadybeen introduced in Shandongprovince where Calan EnvironmentalTechnology is based.

Shandong Province aims to reduceair pollution by 50 per cent in 2020and Eminox’s technology will nowplay a part in achieving this target asits DPF technology has been provento remove more than 90% ofparticulate matter.

“As a leader in exhaust aftertreatment systems, Eminox isreinforcing its market presence

globally, and this Joint Venture withCalan creates a strong foothold inthe Chinese heavy duty dieselvehicle retrofit market,” said NickLyons, Deputy Managing Director ofEminox. “We are confident that ouralliance will enable us to furtherdevelop opportunities across theregion. By leveraging the expertiseof both companies, we have thescope to make a real difference toair quality in the most polluted partsof China.”

Zhaohan Ding, Managing Director ofCalan Environmental TechnologyLtd., said: “We are looking forwardto working with Eminox in our newenterprise.

The Joint Venture will strengthenCalan’s current market presence aswell as play a key role in enhancingour proposition to existing and newcustomers. It brings together bothcompanies' expertise in automotivedistribution and exhaust after-

Eminox Announces Cooperation with Chinese distributor

Eminox set to reduce air pollution inChina

treatment systems.” Air pollution inChina is a growing problem andaccounts for around 1.6 millionpremature deaths every year,equivalent to killing nearly 4,400people every day. Air pollutionalone accounts for 17 per cent of allthe country's deaths. Motor vehiclesin China emit around 52.27 milliontonnes (2010 figures) of pollutantseach year and the number ofvehicles registered is growing at10% annually.

Eminox’s CRT® system is theworld's leading retrofit dieselparticulate filter (DPF) with around60,000 systems installed on busesand trucks worldwide. It enablesvehicles as old as China III to beupgraded to the particulate matter(PM) standards of a China VI vehicle.The CRT® system contains aspecially formulated catalyst and awall-flow ceramic filter. Thistechnology captures particulatematter within the wall flow filter andthen continuously oxidises it, attypical exhaust gas temperatures,into harmless gas using patentedchemical technology.

The FBC System (Fuel Borne Catalyst)provides an alternative dieselparticulate filter solution for vehicleswhich operate with higher sulphurdiesel.

To find out more about the newrange of Diesel Particulate Filtersavailable for Calan EnvironmentalTechnology, go to:www.jialantech.com

For more information on the fullrange of Eminox exhaust after-treatment technology, visit:www.eminox.com or call: 00 44(0)1427 810088.


The UK Department of Health’srejection of an 800,000-signature public petition to

expand the routine administration ofthe only approved vaccine to offerprotection against invasive meningo-coccal disease (IMD) caused byserogroup B (MenB), may lead toparents and physicians to considerpurchasing the vaccine themselves,according to an analyst withresearch and consulting firmGlobalData.

The decision to keep free access toGlaxoSmithKline’s MenB vaccine,Bexsero, limited to infants rather thanvaccinating children up to 11 yearsof age, as requested in the petition,is a significant setback for theadvocacy groups and parentsaiming for expanded vaccineadministration. Mirco Junker, Ph.D.,GlobalData’s Analyst covering

Infectious Diseases, explains: “Eventhough IMD cases caused byserogroups B and C are mostprevalent, the majority of Europeancountries only routinely administermeningococcal vaccines againstserogroup C, which provideexcellent safety and efficacy profilesin combination with relatively lowprice points. MenB vaccines, on theother hand, are relatively new andexpensive, and there is only limitedclinical data demonstrating theirlong-term effectiveness.

“This uncertainty regarding the long-term efficacy - together with studiesindicating low cost-effectiveness ofMenB vaccines - also highlights thegeneral conflicts rare diseases likeIMD bring up when medical needsare pitted against the commercialviability of vaccines. Indeed,vaccinating entire populations

MENB VACCINE BEXSERO MIGHT SEE PRIVATE UPTAKE INTHE UK WITH APPROPRIATE INCENTIVES

against rare diseases can beextremely challenging to rationalizefrom a pharmacoeconomicperspective.”

In fact, in 2014, a study using theanalysis of quality-adjusted life-yearsindicated that the new MenBvaccine would not be cost-effective

even if provided to the NationalHealth Service (NHS) for less than£1 per dose. However, cost-effectiveness should not be viewedas the main determining factor forthe broad application of a vaccineagainst a rare disease, as manyvaccines might not pass thisthreshold, given low enoughdisease prevalence.

Junker continues: “While theDepartment of Health’s decision is adisappointment for parents worriedabout their children developing IMD,GlobalData believes it is understand-able from the perspective of theNHS, as healthcare costs continueto rise and governmental agencieshave to balance the restraints of alimited budget with society’smedical needs. “A reasonablecompromise could be to provideindividual families concerned aboutIMD to purchase vaccines out-of-pocket without having to face thelist price of the vaccine. As such, itmight be in the interest of thepharmaceutical industry to provideincentives to make the vaccineavailable to individuals not coveredunder the NHS guidelines.”


Medanta-The Medicitybrings the revolutionaryFemtoLASIK, the latest and

safest in bladeless refractive LASIKtreatment to the city

Medanta – The Medicity, one ofIndia's largest multi-super specialtyinstitutes located in Gurgaon todayannounced the launch ofFemtoLASIK, a revolutionarytechnology and the most advancedLASIK treatment available in theworld that enables bladelessrefractive treatment.

Speaking on the launch, Dr. NareshTrehan, Chairman and Founder,Medanta said, “At Medanta, it is ourconstant endeavour to bring thelatest medical technologies in theworld to Gurgaon and provide thebest cure to every patient. Thelaunch of FemtoLASIK showcasesour commitment to strengthen ourophthalmology division at theMedicity and provide all encom-passing medical treatment underone roof.”

FemtoLASIK technology is the mostadvanced procedure aimed atimproving patient’s quality of life byreducing the dependence onglasses. This world renowned LASIKtechnology is the current state-of-the-art in refractive surgery. It worksby altering the shape of the corneato treat nearsightedness, farsighted-ness and astigmatism.

Dr. Sudipto Pakrasi, Chairman,Institute of Ophthalmology atMedanta - The Medicity said,

“FemtoLASIK is bladeless and allowsthe creation of flaps with diameterand thickness of a wide range. Itcreates very precise, perfect andsmooth corneal flaps to ensureaccurate treatment with minimumrisk. This is the safest LASIKtechnology available in the worldtoday.”

“With this launch, the Institute ofOphthalmology at Medanta is at parwith other renowned medicalinstitutions globally.” Dr. Pakrasiadded.

About Medanta:Medanta – The Medicity is one ofIndia's largest multi-super specialty

Dr. Sudipto Pakrasi at the LASIK Launch event, Medanta The Medicity

Robotics Lasik Launched inGurgaon

institutes located in Gurgaon, a bustling town in the National Capital Region.Founded by eminent cardiac surgeon, Dr. Naresh Trehan, the institution hasbeen envisioned with the aim of bringing to India the highest standards ofmedical care along with clinical research, education and training. Medanta isgoverned under the guiding principles of providing medical services topatients with care, compassion, commitment.

Spread across 43 acres, the institute includes a research center, medical andnursing school. It has 1250 beds and over 350 critical care beds with 45operation theatres catering to over 20 specialties. Medanta houses sixcenters of excellence which will provide medical intelligentsia, cutting-edgetechnology and state- of-the-art infrastructure with a well-integrated andcomprehensive information system.


The asthma therapeutics marketin the Asia-Pacific (APAC)region will grow from $3.5

billion in 2014 to $5.6 billion by2021, at a strong Compound AnnualGrowth Rate (CAGR) of 7.2%,according to business intelligenceprovider GBI Research.

The company’s latest report* statesthat the primary driver of thisconsiderable rise is the prevalenceof asthma across the APACcountries, which include China,India, Australia, South Korea, andJapan. The condition is burgeoningdue to aging populations andincreases in air pollution, dust andpollen levels, which both cause andexacerbate asthma in children.

Aswini Nath, Analyst for GBI

Research, says: “As well as theincreasing incidence of the disease,six costly biologics are set to enterthe APAC asthma market, which willpush its value up considerably.These consist of GlaxoSmithKline’smepolizumab, Teva’s reslizumab,Chugai/Roche’s lebrikizumab, Sanofi/Regeneron’s dupilumab, andAstraZeneca’s tralokinumab andbenralizumab.

“The most advanced of these drugsis mepolizumab, which is currentlyat the Pre-registration stage in Japan,while the other five monoclonalantibodies (mAbs) are in Phase IIIdevelopment in the APAC region.As the cost of these treatments islikely to be high in comparison withmore established drugs, stronguptake could well increase the cost

Asthma Therapeutics Market in Asia-Pa-cific Region to Hit $5.6 Billion by 2021• Asthma therapeutics market in Asia-Pacific (APAC) region will expand from $3.5 billion in 2014 to $5.6 billion by 2021, as disease prevalence rates rise

• Six costly new biologics will enter the APAC asthma treatment space in the near future, led by GlaxoSmithKline's mepolizumab, says analyst

of treatment for asthma patients.” Interms of disease prevalence trendswithin the five APAC countries, Indiahas the highest number of asthmasufferers. In 2014, 53.6 millionpeople were estimated to be livingwith the disease, which is approxi-mately 52.4% of the total assessedAsia-Pacific prevalence.

Nath elaborates: “Lack of knowledgeof the condition among the public,an increasing aging population, andincreasing air and dust pollution willmean the prevalence rate willcontinue to rise over the period,resulting in 57 million sufferers by2021.

“Despite this, India only represented12.2% of the APAC asthma market in2014, which reflects the low cost of

therapy in comparison with theother assessed countries."

Japan, by contrast, was the largestmarket of the five APAC countries in2014 at $1.8 billion, and willcontinue its lead to 2021, growingto $3 billion at a CAGR of 7.1%,according to GBI Research.

“As Japan is ranked only third of thefive countries in terms of diseaseprevalence, this reflects the relativelyhigh cost of drugs, and thecountry’s readiness to adoptpromising new molecules such asthe IL-targeting mAbs,” the analystconcludes. Asthma Therapeutics inAsia-Pacific Markets to 2021 – HighPrevalence and Launch of Late-StageBiologics will Drive the Market inSpite of Affordability Concerns


Nayati multi super specialtyhospital today organised afree health checkup camp

for women to mark InternationalWomen’s day. The checkupincludes, free consultation by thegynaecologist, free HB and RandomBlood Sugar (RBS) test. In addition,the hospital will offer a special 50%discount to all women on Ultra-sound. The camp will be opera-tional from 9 am – 3 pm.

Talking about the special initiativeNayati Healthcare Chairperson NiiraRadia said “We have launched aspecial initiative “Dharini” for thewelfare of Women’s health. To raisehealth awareness and highlight theimportance of regular health check-ups, we are organizing a freeGynecology Health Check-up and

special discounts on certaininvestigative tests for women underthis special initiative Dharini.Through this initiative we intend toincrease awareness about womenhealth issues that usually remain thelast in the list of priorities in a family.A Woman with a healthy mind andbody can nurture a healthy and fitfamily. A Woman is responsible forthe health condition of her entirefamily therefore the first in her to dolist should be to look after andnourish her own health. ”

Dr. Varna Rao, Head of the Depart-ment Obstetrics & Gynaecologystated “Anemia continues to be amajor public health problemworldwide particularly amongfemales and more so amongfemales of reproductive age and

Uttar Pradesh is no different. TheMaternal Mortality Rate in UttarPradesh is one of the highest. It isimperative that all women takecharge of their health. Women mustfocus on the health of their mindand body in terms of healthy eatingand adequate exercising”.

About Nayati Healthcare & ResearchPvt. Ltd., taking treatment to thepatient: Nayati Healthcare &Research is India’s first Multi Super-Specialty healthcare organisationoffering premium tertiary care to Tier-II & Tier-III cities. It offers world classpatient care services aided by state-of-the-art medical technology andadvanced treatment facilities. Theaim of the organisation is to providecost effective and easily accessiblehealthcare. About Nayati Multi Super

NAYATI MULTI SUPER SPECIALTY HOSPITAL ORGANISESFREE GYNECOLOGY HEALTH CHECKUP FOR WOMENHealthy women Healthy family

Specialty Hospital, Mathura: NayatiMulti Super Specialty Hospital,Mathura once operational will be thefirst hospital in the region to provideintegrated, comprehensive and highquality healthcare through ourCentres of Excellence. Thesecentres will be supported byadvanced Intensive Care unitscomprising of: MICU, CCU, SICU,NICU and PICU. The upcominghospital in Mathura will also cater toVrindavan, Agra, Palwal, Firozabad,Mainpuri, Kasganj, Etawah, Etah,Hathras, Agra and surrounding areas.

About Nayati Center for Excellencein Oncology (Cancer): The Centerhas three divisions: medical, surgicaland radiation oncology, which willprovide end to end treatment forcancer. The centre is concernedwith screening, early detection,grading and management of cancerand has high end radiation therapy,isolation rooms, critical care, bonemarrow transplantation, palliativecare, plastic and reconstructivesurgery, pain clinics and counsellingservices will also be available.

The services at Nayati Center forExcellence in Oncology includeevaluation for solid tumours andblood cancers, along with treatmentplanning and coordination of allmodalities. Minimal access andopen surgical interventions will beavailable for cancer of the head andneck, brain, spinal cord, lungs,pleura, thorax, thyroid, breast,oesophagus, stomach, liver, gallbladder, pancreas, intestine, rectum,gynecological, lymph nodes,kidney, bladder, prostrate andpediatric cancers.

For further information pleasecontact:Shivani Sharma / Neha Singh91 9871741891 / 91 [email protected]/ [email protected]


Merck, a leading science and technologycompany, reported record results for 2015,emerging stronger from the transformation

process that started in 2007. Net sales and EBITDA preexceptionals were higher than ever before in Merck’shistory of nearly 350 years.

“2015 was not only an eventful, but above all a very

successful year for Merck. We againachieved profitable growth. Byacquiring Sigma-Aldrich, wesuccessfully completed theportfolio realignment of recentyears. In immuno-oncology, weinitiated six pivotal clinical trials.Research advances and future-oriented investments form thefoundation for future success. Andour new bold and vibrant brandingshows what makes Merck unique,”said Karl-Ludwig Kley, Chairman ofthe Executive Board.

Net sales of the Merck Group rosesharply by 13.0% to • 12.8 billion in2015 (2014: • 11.4 billion). Theacquisitions of AZ ElectronicMaterials (AZ) and Sigma-Aldrichwere responsible for 4.3% of thesales growth. Organically, Merckincreased sales by 2.6% over 2014.Favorable exchange rate effects,primarily thanks to the strength of theU.S. dollar, contributed 6.2% tosales growth.

The operating result (EBIT) rose by4.6% to • 1.8 billion (2014: • 1.8billion). EBITDA pre exceptionals,the key financial indicator used tosteer operating business, climbedsignificantly by 7.1% to • 3.6 billion(2014: • 3.4 billion) thanks to theLife Science and PerformanceMaterials business sectors.

Net income, i.e. profit after taxattributable to Merck shareholders,

declined in 2015 by –3.7% to • 1.1billion (2014: • 1.2 billion). This wasattributable to one-time expenses inconnection with the Sigma-Aldrichtakeover and integration as well ashigher interest expenses to financethe acquisition.

Earnings per share pre exceptionalsincreased by 5.9% to • 4.87 (2014:• 4.60). The proposal to the AnnualGeneral Meeting on April 29, 2016will be to increase the dividend by •0.05 to • 1.05 per share.

Merck was thus able to meet orexceed its forecast for 2015 withrespect to sales, EBITDA preexceptionals and earnings per sharepre exceptionals.Although Merck had meanwhile builtup a net cash position by mid-2015,net financial debt rapidly increasedas expected to • 12.7 billion at theend of 2015 (December 31, 2014: •559 million) owing to the purchaseprice payment for Sigma-Aldrich. Aswas the case following majoracquisitions in the past, Merck aimsto use its strong internal financingpower to quickly reduce its debt.As of December 31, 2015, Merckhad 49,613 employees worldwide(December 31, 2014: 39,639). Theincrease in the Merck headcount byaround 10,000 people comparedwith 2014 was mainly due to thesuccessful completion of the Sigma-Aldrich acquisition.

Merck Finishes Record Year 2015Stronger Net sales (+13.0%) and EBITDA pre exceptionals (+7.1%) reach new record levels All three business sectors deliver organic growth Asia-Pacific region drives Group sales growth Merck meets targets for 2015 Proposed dividend to increase to • 1.05 (+5%)


Fourth quarter of 2015: Life Sciencedrives Group growthIn the fourth quarter of 2015, Merckgenerated net sales of • 3.5 billion,representing an increase of 15.5%(Q4 2014: • 3.0 billion). Apart fromorganic growth, this was primarilydue to the strong acquisition-relatedsales increase in Life Science. The6.3% increase in EBITDA preexceptionals to • 933 million in thefourth quarter of 2015 (Q4 2014: •878 million) was also driven by LifeScience. At • 1.13, earnings pershare pre exceptionals remainedstable in the fourth quarter of 2015(Q4 2014: • 1.14).

Healthcare: robust business andinvestments in growth marketsNet sales of the Healthcare businesssector increased in 2015 by 4.7% to• 6.9 billion (2014: • 6.6 billion).This was attributable to organicgrowth of 1.6% and exchange rateeffects of 3.1%. Above all, the Asia-Pacific region fueled organic growth.

Sales of Rebif, which is used to treatrelapsing forms of multiple sclerosis,declined organically by –10.7% in2015 owing to continued competi-tive pressure from oral formulations.Amid currency tailwinds of 8.5%,Rebif sales amounted to • 1.8 billion(2014: • 1.8 billion). At • 899million, Group sales of the oncologydrug Erbitux in 2015 were stable(2014: • 904 million). The slightorganic sales decline of –1.5% waspartly offset by positive exchangerate effects of 0.9%. With Gonal-f,the leading recombinant hormoneused in the treatment of infertility,Merck achieved organic salesgrowth of 3.7% in 2015. Includingpositive currency effects, sales roseto • 685 million (2014: • 628million).

At • 2.0 billion, EBITDA preexceptionals of the Healthcare

business sector in 2015 remained atthe previous year’s level (2014: •2.0 billion). This mainly reflected theloss of royalty and license income asof mid-2014 as well as marketingand selling expenses, which weresignificantly higher than in 2014 dueto ongoing investments in growthmarkets as well as currency effects.

Life Science becomes Merck’sgrowth engine in 2015Amid growing profitability, net salesby the Life Science business sectorsoared in 2015 by 25.1% to • 3.4billion (2014: • 2.7 billion). This wasattributable not only to strongorganic growth of 6.5% andfavorable exchange rate effects of8.4%, but mainly to acquisition-related increases of 10.2% resultingfrom the purchase of Sigma-Aldrich.

The Process Solutions business area,which markets products andservices for the entire pharmaceuti-cal production value chain,generated organic sales growth of11.6%. The increase was mainlyfueled by higher demand forproducts used in biopharmaceuticalproduction in Europe and theUnited States. With its broad rangeof products for researchers andscientific laboratories, the LabSolutions business area deliveredorganic sales growth of 3.1%. TheBioscience business area, whichprovides products and services tosupport research for pharmaceuti-cal, biotechnological and academicresearch laboratories, reported aslight organic sales increase of 0.7%.The first-time consolidation ofSigma-Aldrich on November 18,2015 boosted Life Science sales by• 279 million, accounting for 8% ofthe business sector’s net sales in2015.

In 2015, the Life Science businesssector reported a sharp 30% rise in

EBITDA pre exceptionals to • 856million (2014: • 659 million), whichwas attributable to good operatingperformance in all businesses aswell as the contribution from Sigma-Aldrich.

“With the acquisition of Sigma-Aldrich, the biggest takeover in ourcorporate history, Merck hasbecome one of the leading playersin the global life science industry,”said Karl-Ludwig Kley. “We can nowoffer our customers a broaderproduct portfolio than before.Additionally, we now have theleading e-commerce platform in thesector.”

Performance Materials benefits frombusiness with innovative productsIn 2015, net sales of the Perfor-mance Materials business sectorrose sharply by 24.1% to • 2.6billion (2014: • 2.1 billion).

Apart from a significantly positivecurrency effect of 13.1%, revenuesfrom acquired businesses alsocontributed considerably to salesgrowth, accounting for 10.4% of theincrease.

These acquisition-related saleseffects were largely attributable tothe integration of AZ, which wasacquired in 2014. In addition, thefirst-time consolidation in mid-November of the SAFC Hitechbusiness of Sigma-Aldrich contrib-uted around • 10 million to the salesincrease in the Performance Materialsbusiness sector. Organically, netsales were at the previous year’slevel, with growth of 0.6%.

The Display Materials business unit,which was established at thebeginning of 2015, saw a strongincrease in sales driven by currencyand acquisitions and solidified itsglobal market leadership position.

The increases in sales volumes ofinnovative technologies overcom-pensated for the decline in salesvolumes for older liquid crystaltechnologies. For the Pigments &Functional Materials business unit,2015 was a stable business yearwith sales at the previous year’slevel. The Integrated Circuit Materialsbusiness unit, which includes theformer AZ business with materialsused to manufacture integratedcircuits as well as the Sigma-AldrichHitech business acquired inNovember 2015, recorded slightorganic sales growth. Within thePerformance Materials businesssector, the highest growth rateswere achieved by the AdvancedTechnologies business unit. Itsemerging OLED materials businessshowed a particularly dynamicdevelopment. In June 2015, Mercklaid the cornerstone for a new OLEDmaterials production unit inDarmstadt, involving an investmentof around • 30 million.

EBITDA pre exceptionals ofPerformance Materials soared by26.5% to • 1.1 billion (2014: • 0.9billion), driven by currency effects,the integration of AZ, as well asgood volume developments.

2016 guidance: Merck expects slightorganic sales growth and a lowdouble-digit increase in EBITDA preexceptionals

In 2016, Merck expects slightorganic sales growth. Additionally,owing to the acquisition of Sigma-Aldrich, the company expects apositive portfolio effect on sales inthe low double-digit percentagerange. For 2016, owing to theexpected operating performanceand the acquisition of Sigma-Aldrich, Merck forecasts a lowdouble-digit percentage increase inEBITDA pre exceptionals over 2015.


Infinix-i X-ray angiography system--Courtesy of Toshiba

Toshiba agreed to sell its medicalimaging unit to Canon ($CAJ) for¥666.5 billion ($5.97 billion) as itseeks to recover from an ever-worsening accounting scandal.

The price tag and buyer were asexpected, for the process wasdrawn out. But the importance ofthe cash lifeline was heightened bynews that the U.S. Securities andExchange Commission is investigat-ing the company for hiding $1.3billion in losses at its nuclear powerbusiness, according to Bloomberg.

Toshiba's stock fell 8% on therevelation. It's down 64% since its2014 peak due to various otheraccounting mishaps, which have ledto the need for the conglomerate to

slim down.

With earnings of ¥23.9 billion ($210million) on net sales of ¥412.5 billion($3.69 billion), Toshiba MedicalSystems is a bright spot for thestruggling company. It garneredinterest from multiple companiesand private equity firms, as well ascompeting bids from fellowJapanese titans Fujifilm Holdings andKonica Minolta.

Initial estimates were that the sale ofthe entire unit would fetch around$4 billion.

Toshiba Medical Systems consists ofimaging devices for CT scans, MRIs,ultrasounds and X-rays, accordingto the company website. It leads theJapanese imaging market with a 30%share, and is fourth worldwide, with

TOSHIBA TO SELL ITS MEDICAL IMAGING BUSINESS TOCANON FOR $6B AMID DEEPENING ACCOUNTING SCANDAL

a global market share of 10%, NikkeiAsian Review previously reported.

Although most famous for itscameras, Canon's medical deviceofferings include radiographydevices, mobile X-ray machines,fluoroscopy devices and opticalcoherence tomography equipmentfor eye care, according to thecompany website.

It was chosen as the exclusivenegotiator for Toshiba MedicalSystems earlier this month overFujifilm Holdings. Following thedeal's announcement FujiFilm sent aletter to Toshiba inquiring about thesale over concerns it was rushed sothat the transaction can be com-pleted by the end of the company'sfiscal year, which ends in March. "Weare left with an impression that the

deal went through a process thatwas exceedingly tricky and aimed atbuying time," Fujifilm spokesmanTakao Aoki told Bloomberg. "If this isto be accepted, this raises concernsthat competition laws are just afacade."

The deal also calls for ToshibaMedical Systems to pay ¥22.5 billion($200 million) to Toshiba's U.S.holding company for the rights toToshiba America Medical Systems.

Toshiba also said it has come apreliminary agreement to sell itsconsumer electronics business toChina's Midea Group as it narrows itsfocus to nuclear power plants andflash memory chips. It expects topost a net loss of ¥710 billion($6.36 billion) for the fiscal yearending in March.


When Allison Fite was 16,she couldn't stop fallingasleep in class. Doctors

told her it was from a severe sinusinfection, but it never really wentaway. For the next decade shestruggled with infection afterinfection, taking antibiotics anddecongestants. "Having these sinusproblems and not being able tobreathe was debilitating," she says.

Fite, now 27, couldn't figure out whythis kept happening. Neither couldany of her doctors. They told hershe had allergies, but "then the testswould come back and they'd belike, 'Huh. You don't have allergies,' "she says.

But a few unusual symptoms helpedFite eventually figure out that she hada little-known disease shared by 1 to1.5 million Americans. She hasasthma, a loss of smell and taste,and a strong, adverse reaction toalcohol. "Before I could finish [a

drink], I started to get these reallybad headaches," she says. "I reallyam allergic to fun."

And she had nasal polyps, whichare benign growths in the sinuscavities. When she was 20, she hadthem surgically removed for the firsttime. At age 25, she flew back fromwhere she was living in Thailand tothe U.S. for a second operation. Butthis time the polyps reappearedeven faster, a mere eight weeks afterthe surgery.

Allison Fite was living in Thailandwhen she was diagnosed withaspirin-exacerbated respiratorydisease.iAllison Fite was living in Thailandwhen she was diagnosed withaspirin-exacerbated respiratorydisease.

"I was seeing a doctor in Bangkok atthis point," she says. "He was like,'This is not normal.' " But the doctor

mentioned that aspirin can causenasal polyps. This was Fite's first realclue about her illness. It's calledaspirin-exacerbated respiratorydisease, or AERD.

It was first described in the early1900s, says Dr. Tanya Laidlaw, animmunologist at Brigham andWomen's Hospital in Boston whostudies the disease. It's seen in"patients who had this triad ofasthma, nasal polyps and veryidiosyncratic reactions to medica-tions like aspirin," Laidlaw says.

Things started clicking into place.Fite's mother found one of Laidlaw'spresentations on the illness onlineand sent it to her daughter. Fite knewshe had nasal polyps and asthmabut she didn't know if she had thethird symptom — a potentially life-threatening reaction to painkillers likeaspirin or ibuprofen. So her doctorin Thailand decided to test her. Hegave her a fifth of a pill of aspirin, just

Aspirin Both Triggers And Treats AnOften-Missed Disease

to see what would happen.

"Forty-five minutes later," Fite says,"I'm coughing, sweating, my heart isbeating out of my body, and they'relike 'OK, stop. She has the disease.' "

After years of seeing doctor afterdoctor trying to understand why shewas always sick, she finally knew thereason.

"It felt so good to have thediagnosis. I started tearing up in thedoctor's office in Bangkok like mid-horrible reaction," Fite says.

But there was one problem. Fiteneeded a treatment called aspirindesensitization. That's when adoctor overloads a patient with alarge dose of aspirin. And Fite'sdoctor had never done it before.

"He was like, 'I don't feel comfort-able doing it, and I don't think you'llfind a doctor in Asia who is.' " Fitesays.

So Fite left Thailand again and wentto Tanya Laidlaw's clinic in Boston toget the procedure. Laidlaw saysnobody knows why the treatmentworks, but it desensitizes the patientto aspirin and helps alleviate thesymptoms. Laidlaw says she'sfrustrated by the lack of awarenessof AERD. She estimates at least 20percent of people who have it goundiagnosed. "It's really frustrating,"she says.

It probably gets missed a lot byclinicians, particularly primary careproviders who don't specialize inimmunology or ear, nose and throatmedicine, says Dr. Ana Broyles, animmunologist at Boston Children'sHospital. And there's a severe lackof science around the illness. WhenLaidlaw began studying it 10 yearsago, she says barely any basicresearch had been done in the lastcentury.


Conglomerate Ayala Corp. isseeking to expand itsfoothold in healthcare and

education and hopes to seal moredeals this year.

Ayala group head for CorporateStrategy and Development PaoloBorromeo said the conglomeratewants to increase investments inhuman capital through healthcareand education.

“We are looking for investments inhealthcare and education. There area number of opportunities that weare evaluating in (the two sectors),”Borromeo said.

Borromeo declined to confirmwhether there are ongoing talks withsome parties but said the grouphopes to seal some deals soon.

“Hopefully, (we can do it soon).Possibly, we’d like to do that thisyear,” Borromeo said.

He said social infrastructure is veryimportant for the group.

“People tend to neglect socialinfrastructure and are focused onhard infrastructure but (socialinfrastructure) is equally important,”he said.

The country’s oldest conglomeratehas its own line of community-based clinics, FamilyDoc, whichAyala put up through its health-related subsidiary, Ayala HealthcareHoldings.

The group has two community-based clinics, in Las Piñas and inImus, which started in December.

The so-called community-basedclinics, with a size of around 100square meters, have five staff at anygiven time including one doctor andtwo nurses.

With a consultation fee of P350 andclinic hours from 7 a.m. to 9 p.m.,

Ayala expands healthcare portfolio

the clinic is equipped with an X-ray,an ultrasound as well as first-aidresponse equipment.

It is seen complementing thegovernment-run health centers andother community-based clinics.

Depending on the success of thefirst two pilot clinics, Ayala may putup more of these community-basedclinics.

In July last year, Ayala Corp. alsoannounced its venture in healthcarethrough the acquisition of a 50percent stake in drugstore chainGenerika Group.

Its wholly owned subsidiary AyalaHealthcare Holdings signed theagreement with the family of co-founder Julien Bello.

Generika is among the pioneers inthe retail distribution of qualitygeneric medicines in the countrywith over 500 stores nationwide.

Bello and businessman TeodoroFerrer co-founded the drugstorechain.

Established in 2003, Generikapromotes the use of generic drugsin the country. Its first outlet openedin May 2004 in Montillano,Muntinlupa.

In the area of education, Ayala, inpartnership with the Pearson Group,has APEC Schools, which is a low-cost high school chain.


As India’s masses increase inaffluence and awareness,they are demanding access

to better health care. But the supplyof conventionally-delivered healthcare services cannot hope to keepup with the ever-increasing demand.The clamour for specialists able toaddress issues beyond what oftenpoorly-trained general practitionerscan handle is getting especially loud.To understand the scope of theissue, here are the statistics forselected health care specialists inIndia vs the US.

The US is widely considered to havea shortage of specialists, as well as ashortage of primary care physiciansin rural areas. It has suffered fromsuch shortages for decades. Bycomparison, India has a super-shortage of specialists, with lessthan 1 specialist per 1 lakh people.

The US vs India ratio in this caseranges from 5x to 25x. While theseper capita gaps will narrow overtime, it will take many years.So how are the crores of Indians,who have no access to a specialist,going to get help in the next 10years? Providing new means ofaffordable access is no small task.We see five factors that must beaddressed: First, services ofspecialists must not only accessible,but also affordable to both urbanand rural India. Indians have a highwillingness to pay for quality healthcare diagnostics that are reasonablyaffordable. There is growing healthcare consumer awareness in India,so demand will continue to grow ifcare is affordable and accessible.

Second, services must be from atrustworthy source. Because of allthe quacks and healers here, Indians

are generally sceptical unless theycan find genuine medical creden-tials. This is even true of “branded”health care services. People want“board certified” or the equivalentalong with references.Third, convenience is a major factorfor consumers. People lead busylives. If you want to visit a specialist,appointments are hard to get andthen you end up waiting in a queue.For many people, this meanscomplicated logistics with family,cost of transport to a specialistfacility, and lost income. Gettingtreated for the simplest of maladies,too, is an expensive investment.

Fourth, providing consultationneeds to be convenient forspecialists. Most specialists arebusy, so to take on new clients,they need a solution which enablesthem to get more services done in

the same time, and/or to makebetter use of their time when theyare between patients or in transit.Fifth, specialists need to earnmoney. While motivations vary forspecialists, it is fair and right that theyget paid for additional servicesdelivered based on the timeinvested. Ensuring fair remunerationalso helps ensure that they payattention to quality. It must also bereasonably easy for a specialist toreliably receive payment.

Enter the new smart mobileplatforms, which are soon going tobe ubiquitous. The cost of a basicAndroid smartphone is now Rs2,500 and falling. In not too manyyears, it won’t be possible topurchase a new mobile phone thatisn’t a smartphone. India has thecheapest mobile services on theplanet. 3G is already available across

The smart way of providing affordablehealth care


much of India; there will continue tobe a ferocious price war tocapitalise on the 3G and 4Gspectrum purchased by the mobilecarriers. This is all good news forconsumers and health careproviders. Why? Because, thecombo of ubiquitous smartphonesand 3G data creates a massive low-cost platform for delivering healthcare services–the foundation ofTelemedicine 3.0.

Mobile platforms are changing thegame for diagnostics, creatingopportunities for Telemedicine 3.0.Here’s the formula for the future ofdiagnostics by many specialists:Smartphones, tablets and laptops(bring your own) at health clinic.Connected non-invasive diagnosticdevices capture diagnostic andpatient info. Phones/tablets connectsecurely via 3G/4G data to cloud-based apps. Cloud servicesconnect to a network of specialists

using smartphones/tablets, ready toprovide fast responses.

Here are some of the diagnosticservices ready for disruptive growth:Ophthalmology: Eye screening fordisease and refraction issues cannow be done by a technician usingnew low-cost devices such asForus’ 3netra, routed via mobilenetworks to ophthalmologistsworking in their homes, in the backseat of a taxi, or waiting for a flightand diagnosed with a tap on theirsmartphone. In fact, one of ourportfolio companies does exactlythis.

Radiology: CT scans, X-rays,ultrasounds can be captured by atechnician. The remote radiologistscan then view these images alongwith other relevant patient datawherever they are on theirsmartphones, tablets or laptops andprovide diagnosis. Numerous

companies provide this technologytoday in developed markets, andnumerous startups are looking tocreate low-cost versions of thesame in India.

Cardiac care: Today, ECG monitoringdevices are primarily sold to healthfacilities that have a cardiologist innear proximity. If you could easilytransmit an ECG image via asmartphone to a group of on-demand cardiologists, you couldsuddenly put ECG devices in a 100more places.

Dermatology: Eighty-five percent ofskin issues can be fully diagnosedby a dermatologist with a phototaken by a smartphone. From theembarrassing STDs and acne torashes that don’t go away and otherskin issues, there is a huge efficiencyto the consumer and the doctor inmanaging the interactions through amobile platform.

“Diagnostics as a service”: Disruptingand serving

In the next few years, the traditionalmodel of selling diagnostic devicesis going to be replaced with selling“diagnostics as a service”. Ratherthan paying for a diagnostic deviceupfront, a health centre will get a no-or-low-cost device installed and atechnician trained. This device willbe integrated through 3G/4G with agroup of quality specialists who candeliver opinions on patientdiagnostics within minutes. And thebusiness model will be revenuesharing.

This “diagnostics as a service” hasthe potential to increase thediagnostic device market size inIndia in magnitude, connect under-utilised specialists with previously-neglected populations, and usher ina much-needed realisation of thelong-held vision of telemedicine.


You know the drill when itcomes to losing weight: takein fewer calories, burn more

calories. But you also know thatmost diets and quick weight-lossplans don't work as promised. Ifyou're trying to drop a few poundsfast, these expert tips will make iteasy for you to lose the weightquickly.

1. Write down what you eat for oneweek and you will lose weight.Studies found that people whokeep food diaries wind up eatingabout 15 percent less food thanthose who don’t. Watch out forweekends: A University of NorthCarolina study found people tend toconsume an extra 115 calories perweekend day, primarily from alcoholand fat.

Then cut out or down calories fromspreads, dressings, sauces,condiments, drinks, and snacks;they could make the differencebetween weight gain and loss.

2. Add 10 percent to the amount ofdaily calories you think you’re eating.If you think you’re consuming 1,700calories a day and don’t understandwhy you’re not losing weight, addanother 170 calories to yourguesstimate. Chances are, the newnumber is more accurate. Adjustyour eating habits accordingly.

3. Get an online weight loss buddyto lose more weight. A University ofVermont study found that onlineweight-loss buddies help you keepthe weight off. The researchersfollowed volunteers for 18 months.Those assigned to an Internet-basedweight maintenance programsustained their weight loss betterthan those who met face-to-face ina support group.

4. Get a mantra.You’ve heard of a self-fulfillingprophecy? If you keep focusing onthings you can’t do, like resistingjunk food or getting out the door fora daily walk, chances are you won’t

do them. Instead (whether youbelieve it or not) repeat positivethoughts to yourself. “I can loseweight.” “I will get out for my walktoday.” “I know I can resist the pastrycart after dinner.” Repeat thesephrases and before too long, theywill become true for you.

5. After breakfast, stick to water.At breakfast, go ahead and drinkorange juice. But throughout the restof the day, focus on water insteadof juice or soda. The averageAmerican consumes an extra 245calories a day from soft drinks. That’snearly 90,000 calories a year—or 25pounds! And research shows thatdespite the calories, sugary drinksdon’t trigger a sense of fullness theway that food does.

6. Eat three fewer bites of your meal,one less treat a day, or one lessglass of orange juice. Doing any ofthese can save you about 100calories a day, and that alone isenough to prevent you from gaining

the two pounds most peoplemindlessly pack on each year.

7. Watch one less hour of TV.A study of 76 undergraduatestudents found the more theywatched television, the more oftenthey ate and the more they ateoverall. Sacrifice one program(there’s probably one you don’treally want to watch anyway) and gofor a walk instead.

8. Wash something thoroughly oncea week.Whether that’s a floor, a couple ofwindows, the shower stall,bathroom tile, or your car, a 150-pound person will burn about fourcalories for every minute spentcleaning. Scrub for 30 minutes andyou could work off approximately120 calories, the same number in ahalf-cup of vanilla frozen yogurt.

9. Wait until your stomach rumblesbefore you reach for food.It’s stunning how often we eat out

How to Lose Weight:The best ways ever...


of boredom, nervousness, habit, orfrustration—so often, in fact, thatmany of us have actually forgottenwhat physical hunger feels like. Ifyou’re hankering for a specific food,it’s probably a craving, not hunger. Ifyou’d eat anything you could getyour hands on, chances are you’retruly hungry. Find ways other thaneating to express love, tame stress,and relieve boredom.

10. Sniff a banana, an apple, or apeppermint when you feel hungry.You might feel silly, but it works.When Alan R. Hirsch, M.D.,neurological director of the Smell &Taste Treatment and ResearchFoundation in Chicago, tried thiswith 3,000 volunteers, he found thatthe more frequently people sniffed,the less hungry they were and themore weight they lost—an averageof 30 pounds each. One theory isthat sniffing the food tricks the braininto thinking you’re actually eating it.

11. Stare at the color blue.There’s a good reason you won’tsee many fast-food restaurantsdecorated in blue: it functions as anappetite suppressant. So serve updinner on blue plates, dress in bluewhile you eat, and cover your tablewith a blue tablecloth. Conversely,avoid red, yellow, and orange in

your dining areas. Studies find theyencourage eating.

12. Eat in front of mirrors and you’lllose weight.One study found that eating in frontof mirrors slashed the amountpeople ate by nearly one-third.Having to look yourself in the eyereflects back some of your owninner standards and goals, andreminds you of why you’re trying tolose weight in the first place.

13. Spend 10 minutes a day walkingup and down stairs.The Centers for Disease Control saysthat’s all it takes to help you shed asmuch as 10 pounds a year(assuming you don’t start eatingmore).

14. Walk five minutes for at leastevery two hours.Stuck at a desk all day? A brisk five-minute walk every two hours willparlay into an extra 20-minute walkby the end of the day. And getting abreak will make you less likely toreach for snacks out of antsiness.

15. You’ll lose weight and fat if youwalk 45 minutes a day, not 30.The reason we’re suggesting 45minutes instead of the typical 30 isthat a Duke University study found

that while 30 minutes of dailywalking is enough to prevent weightgain in most relatively sedentarypeople, exercise beyond 30minutes results in weight and fatloss. Burning an additional 300calories a day with three miles ofbrisk walking (45 minutes should doit) could help you lose 30 poundsin a year without even changing howmuch you’re eating.

16. Don’t buy any prepared foodthat lists sugar, fructose, or cornsyrup among the first four ingredi-ents on the label. You should beable to find a lower-sugar version ofthe same type of food. If you can’t,grab a piece of fruit instead! Look forsugar-free varieties of foods such asketchup, mayonnaise, and saladdressing. Also, avoid partiallyhydrogenated foods, and look formore than two grams of fiber per100 calories in all grain products.Finally, a short ingredient list meansfewer flavor enhancers and emptycalories.

17. Put your fork or spoon downbetween every bite.At the table, sip water frequently.Intersperse your eating with storiesfor your dining partner of theamusing things that happenedduring your day. Your brain lags your

stomach by about 20 minutes whenit comes to satiety (fullness) signals.If you eat slowly enough, your brainwill catch up to tell you that you areno longer in need of food.

18. Throw out your “fat” clothes forgood.Once you’ve started losing weight,throw out or give away every pieceof clothing that doesn’t fit. The ideaof having to buy a whole newwardrobe if you gain the weightback will serve as a strong incentiveto stay fit.

19. Close the kitchen for 12 hours.After dinner, wash all the dishes,wipe down the counters, turn outthe light, and, if necessary, tapeclosed the cabinets and refrigerator.Late-evening eating significantlyincreases the overall number ofcalories you eat, a University of Texasstudy found. Stopping late-nightsnacking can save 300 or morecalories a day, or 31 pounds a year.

20. Walk before dinner and you’ll cutcalories AND your appetite.In a study of 10 obese womenconducted at the University ofGlasgow in Scotland, 20 minutes ofwalking reduced appetite andincreased sensations of fullness aseffectively as a light meal.


Daily yoga practice at homecan help you stay healthy,more productive, calm and

happy all day. Besides, thesebenefits are not just for you toenjoy. Doing these practices athome will not only keep you happybut your family members too will beable to feel the positive energy andhappiness around. What’s more,you get a chance to practice themright in the comfort of your home,any time you wish.

Once you have learned yogatechniques properly from a Art ofLiving Yoga teacher, and arecomfortable, you can startpracticing them on your own. Hereare a few tips to keep in mind asyou prepare yourself for a fun yogapractice at home.

1: Choose a convenient timePracticing yoga in the morning isgenerally considered to be the bestas it keeps energy levels high duringthe day. Yet, if it doesn’t happen,don’t let it be an excuse to skip yourpractice. You may choose a timeslot which seems most convenient.It could be late mornings, before

lunch, or evenings. Yoga at thesetimes can also be a good way torefresh the mind and release stresscollected during the day.

2: Choose a comfortable placeIt would be best to have a small,private room in your house for dailyyoga practice. Over time, yourpractices will create positivevibrations in the room, providinghealing, strength and comfort to youand others at home. However, incase it is not possible, you maychoose a quiet space anywhere athome, which is large enough to rollout your yoga mat and where youknow you are not likely to bedisturbed for a while. All you needto ensure is that your yoga space isclean, well-ventilated, and awayfrom furniture or sharp objects (learnmore about a yogis home).

3: Practice on a relatively emptystomachYoga postures are always bestpracticed on a light or emptystomach. You can practice yogaposes and meditate about 2-3hours after your meal.

4: Keep your yoga wear simpleGo for loose, comfortable clothing– you wouldn’t want tight body-hugging outfits coming in the way ofdoing some wide stretches! Also,keep aside any excessive jewelrythat you are wearing and avoidheavy makeup.

5: Warm up before doing intenseyoga posturesThis is an absolute must, else youmay be at risk of straining yourmuscles. Start by warming up yourbody and do a few body stretchesto bring flexibility, before moving onto more intense yoga postures.

6: It is your own body; be gentle onitRespect your body and do yogaposes gently with a smile. Doingthem increasingly fast or goingbeyond what your body can takewill not bring faster results. It will onlymake the practice more difficult andpainful.

7: Be consistentIt is very important to be regular withyour yoga practice – make it a partof your daily schedule (as men-

9 Tips to Practice Yoga at Home

tioned above, find a time slot whereyou can comfortably fit yoga in) andthen it would be easier to make it ahabit. Krishan Verma, senior Art ofLiving Yoga teacher says, "Twentyminutes of daily yoga practice ismore likely to show positive resultssooner than two hours of occa-sional practice."

8: Make yoga time as ‘family funtime’When you practice alone, it mightget boring after a while or you maysimply become lazy. Try doing itwith family or friends and see thedifference! Practicing yoga at homecan be a great way for a family get-together. Learn more about how youcan enrich your family time withyoga.

9: Include a variety of yogatechniquesPractice a variety of yoga poses andbreathing techniques, or if you arecrunched for time, you may fix a setof practices to be done daily andthen treat your body with thecomplete package on a Sunday!Also, be sure to end your yogapose practice with Yoga Nidra.


Yoga is considered as one ofthe the best and simplest waysfor weight loss. The best thing

about yoga is that it can bepractised by people of any age as itis equally good for any age group.Even pregnant women are recom-mended to do Yoga because it canbe healthful during the period aslong as they take certain precau-tions.

Stress has been linked to manyhealth problems including gainingweight. Yoga, which is believed tobe a good stress buster, will notonly help you stay in shape, but willalso reduce your risk of gettingcertain diseases. Losing weight andstaying fit can help boost a person'sself-esteem and decrease stresslevels.

Below are a few yoga poses that willpromote weight loss if onepractices it regularly:

Bridge poseBridge pose(Chakrasan): This is a powerful yogapose for flattening your tummy by

toning and strengthening theabdominal muscles along with thehip flexors and spine.

Lie down on your back, bend yourknees and keep your feet flat on thefloor hip distance apart.Move your hands alongside thebody with the palms facing downand make sure that your fingertipsare lightly touching the heels.You can clasp your hands togetherand now lift your body in theupward. Hold this pose for 30seconds to 1 minute.Release and roll slowly back to thefloor. Repeat 5 more times.Cobra poseCobra pose(Bhujangasan): This yoga pose isusually done to firm the buttocksand tone the abs. It is also a greatexercise for people with backaches.

Lie face down on the floor.Place your hands under yourshoulders, palms flat and fingersspread apart.

Stretch your legs with the tops of

Yoga tips for weight loss: Five waysto slim down your tummy and thighs!

your feet flat on the floor.Press your palms into the floor andlifting your head and chest upward.Push back your shoulders whilekeeping your hips, legs and feetplanted on the floor.

Bow poseBow pose (Dhanurasan):This yoga pose may take moreenergy to do, but it really helps youburn fat and tone difficult parts ofthe body. Bow also helps relievemenstrual and constipationproblems.

Lie down on your belly and reachyour back with your hands to grabyour feet as in bow pose.Now, pull in your stomach and liftup your chest while squeezing yourshoulders towards each other.Your feet should be folded towardsthe hip region with the handsholding the toes.Hold this pose for several breathesand then slowly release.Seated forward bend poseSeatedforward bend pose(Paschimottanasana): This is one ofthe simplest yoga exercises to

reduce the unwanted fat surround-ing your belly while keeping you fitand healthy.

Sit down on the floor with bothyour legs keeping straight in front ofyou.Bend your head and body forwardand try to touch your toes withoutbending your knees.Try to touch your knees with yournose or forehead.Exhale and holding out your breath,try to stay in this posture for a fewseconds and then slowly return toyour starting position.Repeat this for 4-5 times.Grinding poseGrinding Pose (ChakkiChalanasana): This is a very effectiveasana to reduce belly fat.

Sit comfortably on the floor withyour legs spreading straight in frontof you.Make sure that both your legs toucheach other.Now, clasp both your handstogether and move it in a circularmotion without bending your knees.Do it 10 times in clockwise position.


EHR makers including Allscripts,athenahealth, Cerner,drchrono, Epic and McKesson

said they will embrace open specsincluding S4S APIs and FHIR toconnect research apps to electronichealth records software.

The National Institutes of Health andthe Office of the National Coordina-tor for Health IT have launched Syncfor Science, a pilot to allowindividuals to send their health datato researchers with the PrecisionMedicine Initiative.

The S4S pilot – coordinated by NIHand ONC alongside the HarvardMedical School Department ofBiomedical Informatics – will be keyto helping the Precision Medicine

Initiative Cohort Program reach itsgoal of including one million U.S.participants. Key to S4S' success,meanwhile, will be the electronichealth record vendors taking part inthe project: Allscripts, athenahealth,Cerner, drchrono, Epic andMcKesson.

The vendors will implement a"consistent, standards-basedworkflow," building on openspecifications such as OAuth andHL7's FHIR protocol, according to ablog post co-written by DeputyNational Coordinator Jon White, MD;Josephine Briggs MD, interimdirector of the PMI Cohort Program;and Josh Mandel MD, researchscientist at Harvard Medical School."Once developed and imple-

NIH AND ONC ANNOUNCE SYNC FOR SCIENCE TOENABLE PATIENTS TO DONATE DATA TOPRECISION MEDICINE INITIATIVE

mented, this functionality will allowindividuals to connect a researchapp to their electronic health data,facilitating individual data donationfor research and leveraging patients’access rights under HIPAA," theywrote. "The pilots will also collectinformation on individual participantpreferences on alternative ap-proaches for data donation."

S4S pilot has two goals: Make iteasier for patients to share clinicaldata with the PMI Cohort in astructured electronic format, andbuild up a national ecosystem forpatient-mediated data accessthrough APIs. Stage 3 meaningfuluse requires APIs, for instance, andWhite said the S4S pilot offersinsight into how that requirement

could play out across the market.

ONC and NIH are hoping that theAPIs developed as part of the S4SPilot will offer research participantseasier ways of sharing medicalrecords; researchers an easier pathto receive basic clinical data;providers a way to improve patientengagement, and vendors newways to help their customers meetmeaningful use requirements for forAPI-based patient access.

ONC said EHR vendors should joinArgonaut’s free, open Implementa-tion Program to get involved in S4S.The agency also encouragedproviders whose vendors areparticipating in S4S to offer to serveas a pilot site.


The trend can no longer beoverlooked. Many employers inthe field of medical technology

complain of a lack of experts andmanagers in the case of engineers,scientists, and IT specialists. There isa lack of candidates with andwithout professional experience. Atthe same time, more than 20,000 ofthe total 130,000 visitors to theMEDICA 2015 already stated thatthey also visited the world’s largestmedical trade fair (recently featuringalmost 5,000 exhibitors from 70countries) to gain career perspec-tives.

Based on this development, fromthis year on, the MEDICA will includethe “T5 Career Forum” to cover the

At the MEDICA 2016, the “T5 CareerForum” is going to start

topics of recruiting and careerplanning. The forum will be plannedand implemented in close coopera-tion with the T5 KarrierePortal – as aplatform for employers as well asexperts and managers. “In the firstyear, as a joint effort, we would liketo test how large the true need reallyis for employers as well as candi-dates and what other topics mightbe of interest,” explained Klaus PeterKaas from the T5 KarrierePortal.

The cooperation between theMEDICA and the T5 KarrierePortalalso stretches into the online area,reciprocally linking an electronic jobmarket with the portals at“MEDICA.de” and “T5-karriereportal.de” (Link: http://

www.medica-tradefair.com/tcf2).

The MEDICA 2016 will be held from 14 to 17 November in Düsseldorf,running, as in the previous year, from Monday to Thursday. In parallel to theMEDICA 2016, the COMPAMED 2016 will be taking place, the internationallyleading specialist trade fair for suppliers of the medical technology industry(in 2015: 779 exhibitors from 37 countries).


Leading providers are alreadythinking about how totransform themselves from

data-driven to information-drivenorganizations, able to offerdrastically improved patientexperience akin to Amazon andGoogle. But it's not easy.

Seattle Children's Chief Data OfficerEugene Kolker offered up aconfession: "I'm a little bit nervousright now about what's happening inour industry. People are movingfrom one extreme to another."

His main concern? Healthcareproviders and payers that arefocusing on cost above all else.With changing payment models,shared savings and risk and patientsempowered by everyday technolo-gies, Kolker said, this new age

requires providers to concentrateon so much more than the bottomline.

"We have to drastically improveexperience for our customers,” headded. “In the next five years we'llhave really different customers.They'll have a Google- or Amazon-like experience to compareproviders by outcomes andexpense, and they'll be able to dothat conveniently with phones theyhave right now."

Addressing that demand is going torequire putting big data and analyticsto work in new ways — and leadinghealth institutions are already thinkingabout how to transform data intoinformation. In addition to SeattleChildren’s, some of the first-moversinclude Advocate Healthcare and

Brigham and Women’s.Healthcare doesn't have big data —yet

Despite all the buzz around bigdata, a smaller reality persists.

"I haven’t seen healthcare big data.I've only seen healthcare little data,"said Sriram Vishwanath, a professorof electrical and computer engineer-ing at the University of Texas, Austin."Healthcare data science isfundamentally different than everyother domain. Healthcare isexponentially harder."

One reason: Within a population oftens of millions of patients,Vishwanath explained, it's typical thatonly a few hundred thousand areultimately driving cost and treatmentpatterns.

What's more, privacy concerns areinhibiting healthcare organizationsfrom easily linking information topatients, according to KennethMandl, MD, a professor of Pediatricsat Harvard Medical School and theBoston Children's Hospital Chair inBiomedical Informatics andPopulation Health.

"There's a reason we don't havemuch data linked to the patient:privacy," Mandl added. "One issue inhealthcare is that the data doesn'tlink very easily."

Those are among the reasons that,according to Deloitte, only 16percent of healthcare organizationsare doing anything beyond dabbling— some analytics pilots, perhaps, orproofs-of-concept.

BIG DATA: BOLD PROMISE? OR THE HARDESTPART OF POPULATION HEALTH, PRECISION MEDICINEAND BETTER PATIENT EXPERIENCE?


"Most organizations are only able totap into retrospective views; they'renot ready to use analytics to providemore advanced insights into thebusiness," said Ryan Renner, principalof Deloitte's Strategy and Operationsanalytics leader.

From data-driven to information-driven

The next step to enhancing thepatient experience en route topopulation health management andprecision medicine practices istransforming data intoinformation?The difference betweendata and information is more than anuance or naming convention. Andwith population health, genomics,precision medicine all on thehorizon, there are some emergingsuccess stories of providers runninganalytics against data sets to gleanactionable information.

David Bates, MD, chief innovationofficer at Brigham and Women's, forinstance, rattled off high-costpatients, readmissions, triage,decompensation, adverse events,diseases that affect multiple organsystems as areas where he has

already seen early demonstrableprogress.

"It's not just about the data — data isnot the most key aspect anymore,"said Tina Esposito, vice president ofthe Center of Health InformationServices at Advocate Healthcare. "It'show you turn it into information."

Taking that a step further, ChrisKeaton, director of information andanalytical advancement atHealthNow New York, said hisintention is no longer to be a data-driven organization.

"I want to strive to be an information-driven organization. That's my goal,"Keaton explained. To which SeattleChildren's Kolker added: "We'retrying to get from data to execution."

In the future data will be big

Advocate's Esposito said thatproviders will be looking to exploreways of tying information together tobetter understand characteristics ofpatients and populations than wedo today.

"The number of data sources that

could be pressed into use are huge," Mandl said. "There are ways to makebig data sing and dance if we align with workflows."

That won't be easy. As the digital world moves toward IDC's projected 44zettabytes by 2020, in fact, the challenge of examining all that data is findingemployees with the right skill sets, engaging leadership to ensure projectssucceed, having clean processes to communicate with customers andhaving a tight, iterative development cycle, according to JonathanGreenberg, director of Fast Analytics at the University of Michigan HealthSystem.

"Now a lot of data are collected electronically but it does take a lot of workto get all the data out the back – we’re working to make that a sustainablecore feature of healthcare," Mandl explained. "We can get the data out now,and do studies at scale. But how do we influence at the point of care itself?"


CIO Craig Richardville saidCarolinas has reduced itsduplicate medical records

error rate from 2.9 percent to 0.01percent using the ID and authentica-tion technology in conjunction withits master patient index.

Carolinas HealthCare System hasreduced its duplicate medicalrecords error rate from 2.9 percentto 0.01 percent using ID andauthentication technology. Thatimprovement, in turn, has helpedbolster the health system’s patientsafety initiatives, which CIO CraigRichardville called the ultimate returnon investment for the technology.

“We were looking at it to uniquelyidentify patients, especially in anelectronic health records environ-ment, where problems withduplication of medical records, errorrates, incorrectly combining records,and finding a perfect patient matchget accentuated,” Richardville said.“In a manual world, you can pull

information out and combinerecords fairly easily. In an electronicworld, incorrect data potentially canget integrated.”

Additionally, Carolinas uses clinicaldecision support technology alongwith its EHRs, and if patientinformation getting pumped into thedecision support system isincorrect, that can lead to improperguidance for providers, Richardvillesaid.

So Carolinas went with Imprivata’spalm-vein biometrics to comple-ment its enterprise master patientindex. When being admitted intoany facility, a patient age 13 or olderplaces his or her hand atop thepalm-vein scanner, which on the firstscan identifies the unique veinpattern underneath the skin andassigns that pattern an algorithm andunique identification number withinthe enterprise master patient index.After that, no matter the Carolinaslocation that patient enters, the palm

Carolinas HealthCare boosts patientsafety with palm-vein biometrics

scan will link registrars and caregiversto that patient’s proper andcomplete records.

Richardville said that 97 percent ofpatients have accepted thetechnology and agreed to palm-veinscans.

“We still have 3 percent or so whodo not want to use it, which may beover privacy concerns, a religiousconcern having to do with the palm,or a lack of understanding of thisone additional thing we’re lookingto capture from them,” he ex-plained.

Richardville said Carolinas didconsider other biometrics technolo-gies.

“We looked at iris recognition, but itwas more expensive and to somepatients it felt intrusive to havesomething looking into your eye,even though it’s just a camera takinga picture,” Richardville said. “We

looked at fingerprint, which was lessexpensive, but there were manyfalse positives. That error rate wastoo high, and we thought we werehitting a better rate even with manualthan with fingerprint, so it did notgain us a significant advantage.When we did our pilots, people feltmost comfortable with palm-veinscans.”

In addition to reducing the duplicatemedical record error rate, thebiometrics technology has helpedidentify unconscious trauma patientsin emergency rooms and hashelped the health system avoidsome cases of insurance fraud,Richardville added.


Tested at YMCA, this marks the firsttime a CMS Innovation Centerpreventative service has becomeeligible for expansion in Medicare.

Chalk up a big win for diabetesprevention. Health and HumanServices Secretary Sylvia Burwellannounced Wednesday that apreventive model of care for peoplewith diabetes is indeed working.And now the Centers for Medicareand Medicaid Services is consider-ing how it would expand this modelbroadly throughout the Medicareprogram.

This is the first time a preventiveservice model from the CMSInnovation Center has becomeeligible for expansion into theMedicare program.

YMCA of USA used $11.8 million infunding, under the Affordable CareAct, to test the Diabetes PreventionProgram model. YMCA enrolledeligible Medicare beneficiaries athigh risk for diabetes in a lifestylecoach program focused on

improving diet and increasingphysical activity. The target was a 5percent weight loss.

The proof is in the results: Medicarebeneficiaries enrolled in the programlost about 5 percent of their bodyweight, and more than 80 percentof participants attended at least fourweekly sessions. Also, whencompared with similar beneficiariesnot it the program, Medicareestimated savings of $2,650 for eachenrollee over a 15-month period,more than enough to cover the costof the program, according to CMSactuaries.

"This program has been shown toreduce healthcare costs and helpprevent diabetes,” Burwell said in astatement. “Medicare, employersand private insurers can use [themodel] to help 86 million Americanslive healthier.”

About 30 million Americans havetype 2 diabetes, resulting in twodeaths every five minutes across thecountry. Moreover, 86 million

Diabetes Prevention Program under theAffordable Care Act is working

Americans have a high risk of developing diabetes, because one in everythree adults has prediabetes, according to the Centers for Disease Controland Prevention. Many people with prediabetes develop type 2 diabeteswithin 10 years, according to the CDC.


Motion sickness is common,especially in children. Butwhat causes it is only partly

understood, and why somechildren have it and others do not isunknown.

Carsickness isn't really about the car.It's about the brain's ability tointerpret a message based on whatit senses. Normally, the eyes, ears,and joints all send signals to thebrain, and the signals are similar,according to the AmericanAcademy of Pediatrics. If you'retraveling in a car, most body partstell the brain: "We're movingforward."

But if the child is sitting too low tosee through the window to the

horizon or the child is looking downand reading at the same time, hisbrain is getting different messages.The part of the ear that controlsbalance and motion says, "We'removing," but the message from theeyes says, "We're sitting still andlooking at a book!" This leads to asensory mismatch that overloadsand confuses the brain, and nausearesults. This can be a problem if yourchild is not looking out thewindshield. If your children are tooyoung to express themselves, youcan suspect carsickness if theybecome bad-tempered, sweaty,and pale, are restless, or begin toyawn frequently.

Here are several tips to preventcarsickness: Stop frequently and at

Why Children Get Carsick—and Whatto Do

the first sign of symptoms. Beforeleaving home, give your child somecrackers or other light snack. Avoidsmoking or carrying any strong-smelling foods in the car.

Elevate your children (with ap-proved child safety seats or boosterseats) so that they can see thehorizon through the windshield.Remember, though, that childrenunder 2 years old need to be inrear-facing car seats (unless theyhave reached the highest weight orheight allowed by the car seatmanufacturer).

Entertain young children withactivities that keep them fromlooking down. Instead of usingbooks, try CDs they like to listen to.

If your children get carsick, stopimmediately and have them lie downuntil the dizziness passes. If theyhave vomited, offer cool water anda light snack when the nauseapasses.

If carsickness is a regular problem,talk to your child's health careprovider. If your child is older than 2,your health care provider maysuggest an over-the-counter travel-sickness medication. Be sure to usethe proper dosage for the child'sage. Some of these medicationscause sleepiness or even agitation.Always get advice from your healthcare provider and be careful whenusing them. Do not use a motionsickness patch because it containstoo high a dosage for children.


What's the difference between a bad case of the blues and the painfulmental disorder known as depression? According to the experts, impairedfunctioning is usually a clear-cut indication of a major depression.

Here's a quick checklist of depression symptoms. If the list sounds familiar,you may want to see a counselor or a psychiatrist.

Depressive mood. Do you suffer from feelings of worthlessness, helpless-ness, or pessimism for days at a time?

Sleep disturbance. Do you have trouble falling asleep at night or troublestaying asleep—waking up in the middle of the night or too early in themorning? Are you sleeping too much?

Chronically fatigued. Do you frequently feel tired or lack energy?

Isolation. Have you stopped meeting with family or friends? Increasingisolation and diminished interest or pleasure in activities are major signs of

A Safer Way to Get Out of BedSomething as simple as getting out of bed properly can help to ease strain on your back and prevent injury. Follow these steps to protect your back whenyou get out of bed: Move yourself close to the edge of the bed while still lying on your back. Bend your knees upward and flatten your feet on the bed. Rollonto your side closest to the edge of the bed, keeping your knees together. Keep your shoulders in line with your hips — don't twist your spine as you roll.

Once you're on your side, use both hands to push yourself up into a sitting position. Let the weight of your legs swinging to the floor help you move. Whenyou're sitting up, take a moment to rest and take deep breaths, if needed, particularly if you're feeling lightheaded. When you're ready to stand up, leanforward. Use your legs and arms to push yourself up to a standing position. Tighten your stomach muscles to help keep your back straight.

Once you're standing, straighten both of your legs at the same time.

A Checklist for Depression

depression.

Appetite disturbance. Are you eating far less than usual—or far more?Severe and continuing appetite disturbance is often an indication ofdepression.

Inability to concentrate. If you can't seem to focus on even routine tasks, it'sprobably time to get some help.

Dependence on mood-altering substances. If you depend on alcohol orother drugs to make it through the day, you may be suffering from depres-sion. Often, the substance abuse causes symptoms that mimic theappearance of clinical depression, but are, in fact, due wholly to the druguse.

Feeling a sense of inappropriate guilt

Recurrent thoughts of death or suicide or a suicide attempt


You can avoid the flu thisseason by taking 1 simplestep: Get a flu shot.

Unfortunately, some people thinkthat getting a flu immunization is toomuch trouble or costs too much.Or, they are sure that a flu immuniza-tion will make them sick or makethem more likely to catch the flu oreven colds.

Seasonal influenza — the flu — iscaused by 1 of several strains ofinfluenza viruses (type A or B) thatinfect the nose, throat, and lungs.The flu makes life miserable for aweek or 2 for many people — anddeadly for some. Flu season canbegin as early as October and peakanywhere from late December toearly April, according to the CDC.

Immunization facts

Your best defense against the flu isto get immunized. Depending onyour age, you can do that in 1 of 2ways:

With a flu shot, given with a needle.This form of the vaccine containskilled virus and is approved for allpeople older than 6 months of age.

With a nasal-spray vaccine. This form

contains live, weakened flu virusesthat can't cause the flu. This form isapproved for healthy people ages 2to 49 years. Exceptions are thosewho are pregnant or have diabetes,a weakened immune system, heartproblems, or chronic respiratorydisorders like asthma. Check withyour health care provider to see ifthe nasal-spray vaccine is right foryou.

A flu immunization is most importantfor children 6 months to 59 monthsand adults ages 50 and older. It isalso important for anyone with achronic disease, anyone who livesin a nursing home or other long-termcare site, health care workers, andpeople who are often in contactwith elderly adults or the chronicallyill.

The CDC says children betweenages 6 months and 8 years whowere never immunized or receivedonly 1 dose of vaccine in theprevious year should get 2 fulldoses of vaccine, 1 month apart.

Health care providers also suggestflu shots for women who plan to bepregnant during flu season. The CDCsays flu shots are OK forbreastfeeding mothers.

Even if you don't fall into 1 of theabove groups, you can still get thevaccine if you want to avoid the flu.Talk with your health care providerfirst

Some people shouldn't beimmunized for the flu before talkingwith their health care provider, theCDC says. These are reasons to talkwith your health care provider:

You have a severe allergy — like ananaphylactic reaction — to chickeneggs.

You had previously developedGuillian-Barré syndrome in the 6weeks after getting a flu shot.

You currently have an illness with afever. Wait until symptoms improvebefore getting the vaccine.

Children younger than 6 months ofage should not be immunizedagainst the flu. Flu vaccines haven'tbeen approved for that age group.

Other prevention steps

Flu viruses are spread by contactwith droplets sneezed or coughedfrom an infected person. Inhaling thedroplets is the most common routeto getting the flu. Touching objects

A Simple Way to Keep the Flu Awayon which droplets have landed alsoinfects many people. You canspread the virus to others beforeyou feel sick yourself. The CDC saysyou are contagious a day beforesymptoms begin and up to 5 daysafterward.

You can protect yourself against theflu by doing simple things likewashing your hands before eatingand not putting your hands nearyour face or in your mouth. Youdon't need special cleansers whenwashing your hands. Washing for atleast 20 seconds with ordinary soapworks fine. If someone in your familyhas the flu, you can keep surfacesclean of the virus by wiping themwith a solution of 1 part bleach to10 parts water.

The other effective means of fluprevention is humidity. The flu bugexists in higher quantities in dry nasaland oral passages, which is 1 reasonwhy flu epidemics occur in drywinter months. Raise the humidity inyour workplace and at home tokeep your nasal passages andmouth moist. Your body will then bebetter able to flush out the flu bug.

Rooting out rumors

Don't believe the rumor that a flushot can give you even a mild caseof influenza. It's impossible. Neitherform of the vaccine — by injectionor nasal spray — contains a form ofthe flu virus that can give you the flu.The injected form of the vaccine ismade from pieces of dead flu viruscells. The nasal spray contains liveviruses that have been damaged sothey can't cause a major infection.

When you are injected with the fluvaccine, your body reacts as if it hasbeen infected with the actual livingvirus and makes antibodies thatprovide immunity against the realvirus. These antibodies remain athigh levels for only 6 months to 9months. These disappearingantibody levels are 1 reason whyyou need to be revaccinated eachyear.


Surveys show that few womenthink heart disease is theirgreatest health threat.

Unfortunately, it's the nation'snumber one killer, and women areits prime target. Over one-third ofthe women who die in the U.S.each year die of heart disease. Infact, more women die of heartdisease each year than breastcancer.

The risk of heart attack and strokeincreases with age. That’s especiallytrue after menopause. But youshould start protecting yourself fromheart disease early. The buildup ofplaque in your arteries—calledatherosclerosis—can lead to heartattacks and strokes. It can begin asearly as your teens and 20s.

Check your risk

Talk with your health care providerabout your cholesterol and bloodpressure. Have both checked. Thehigher either of them is, the greateryour risk for heart disease or heartattack. A blood test done after a 9-to 12-hour fast can measure the fatsin your blood. It can tell you:

Your total cholesterol

LDL ("bad") cholesterol

HDL ("good") cholesterol

Triglycerides, another form of fat inthe blood

But your cholesterol is only part of it.Your health care provider will look atyour medical history. He or she willalso ask about your family history ofheart disease.

This information will help assess yourpersonal risk for the disease. He orshe may decide you need medica-tion to lower your cholesterol. Oryour health care provider may wantyou to make lifestyle changes beforeprescribing medication.

For some women, heart disease ispreventable. The following lifestylechanges can help women lowertheir risk for it.

Maintain a healthy weight

Being overweight can raise yourblood pressure, cholesterol, andtriglyceride levels. It also puts you atrisk for type 2 diabetes. Thiscondition can also raise your risk forclogged arteries and heart attack.

By losing weight, you'll lower yourcholesterol and blood pressure.You’ll also be less likely to developdiabetes. Even losing 5% to 10% ofyour body weight can make adifference. Talk with your health careprovider about your weight.

Quit smoking

Smokers have more than twice therisk for heart attack than dononsmokers. The chemicals incigarette smoke can shrink coronaryarteries, making it tough for blood tocirculate. Smoking can also causethe lining of blood vessels tobecome stickier. As a result, bloodclots are more likely, which cancause stroke.

Get active

Strive for at least 30 minutes ofmoderate-to-vigorous physicalactivity 5 days a week. Exercise canreduce your risk of heart disease. Itcan raise your good cholesterol andlower your bad cholesterol.

Change your fats

Change the fats in your diet. Avoidbutter and other saturated fats.Instead use liquid margarine, tubmargarine, olive oil, and canola oil.But use them sparingly because allfats are high in calories. Each type offat contains roughly 100 calories pertablespoon. Too much dietary fat ofany kind can lead to weight gain.

Also limit the following:

Full-fat dairy products

A Woman's Guide to Beating HeartDisease

Fatty meats

Palm oil

Partially hydrogenated vegetable oils

Convenience or other preparedfoods high in fat

Eat your fruits and veggies

Eat plenty of produce. A moderatelyactive woman should eat at least 3cups of vegetables and 2 cups offruits daily. Studies link diets high infruits and vegetables with lowerblood pressure and a reduced riskfor heart disease.

Fiber up

Soluble fiber helps reduce LDLcholesterol. Oatmeal, whole-grainbread, and other whole-grain foodsare excellent sources of this nutrient.Adults should have 6 to 9 ouncesof grains per day. Half of this amountshould be whole grains.

Drink alcohol only in moderation

Women should limit alcohol to nomore than 1 drink per day. That’sequivalent to 12 ounces of beer, 4to 5 ounces of wine, or 1-1/2ounces of 80-proof spirits.


Most stomachaches arenothing more thanindigestion or gas. But

stomach pain also could beappendicitis, gallstones, a tubalpregnancy, or other seriousconditions. The features of the painand its severity, location, andduration are clues to its cause.

What to ask

These are questions to considerwhen describing the pain to yourhealth care provider:

Where is the pain? Is it in the upper,middle, or lower abdomen? Is it onone side only or on both sides?

Does the pain stay in one spot ordoes it seem to travel?

Is it related to eating or going to thebathroom?

Does it come and go or stay thesame?

Does anything make it worse orbetter?

Other important things to tell yourhealth care provider:

Whether you have vomited or havediarrhea

If you had blood in the vomit,diarrhea, or urine

Whether you have shortness ofbreath, dizziness, or a fever

The usual suspects

Gastroesophageal reflux disease(GERD), a cause of indigestion andheartburn, and inflammation in thestomach are the most commoncauses of stomach problems.

A stomach viral infection, alsoknown as gastroenteritis, can causesymptoms that include nausea,vomiting, cramps, diarrhea, andfever. It usually goes away withoutmedical treatment.

Food poisoning causes nausea,vomiting, stomach cramps, anddiarrhea. Symptoms can occurwithin 30 minutes or up to 2 daysafter eating contaminated food.

Gallstones can cause steady pain inthe upper belly that increases rapidlyand lasts from 30 minutes to severalhours. Other signs include bloating,gas, and indigestion.

Irritable bowel syndrome is one ofthe most common disordersdiagnosed by health care providers.Belly pain, bloating, and discomfortare the main symptoms.

Appendicitis requires immediatemedical attention. The symptomstypically start with a loss of appetite,mild fever, pain around thebellybutton, vomiting, diarrhea, or

constipation. The pain usually movesto the belly's lower right side.

Diverticulitis can feel like appendici-tis, except the pain is in the lowerleft side of the belly. The pain isusually severe and comes onsuddenly.

Ectopic or tubal pregnancysymptoms include belly or pelvicpain. It can be sudden, constant,and severe but also may be mild. If afallopian tube has burst, which is amedical emergency, there also maybe signs of shock like a weak, racingpulse; pale, clammy skin; anddizziness or fainting.

Ovarian cancer symptoms caninclude periodic pelvic andabdominal pain. Other symptomsinclude more frequent urination anda more frequent urge to urinate;increased belly pain or bloating; anda feeling of fullness.

Treatment decisions

About Stomachaches

The following guidelines can helpyou determine how to respond tostomach pain:

Self-treat if the pain is mild.

See your health care provider if thepain is mild to moderate andhappens again over time.

Go to the emergency room if yourpain is severe, if you have a fever, ifyou have blood in your vomit, or ifyou have bowel movements thatlook like runny, black tar.

A health care provider shouldevaluate any pain that’s severe orinterferes with your ability to goabout your usual routine.


When you are rolled intothe operating room atthe hospital, you want to

know that the surgeon is ready toconcentrate on your procedure.When you board a jetliner for yournext vacation destination, you wantto know that the tower crew isrested and ready to direct the pilotthrough dense airport traffic.

Concentration is vital in someprofessions. Even in our everydaylives, though, we all need toconcentrate — to avoid trafficaccidents, to get the job finished, toremember important information.But with today's world filled withflashing images on TV, quick newsreports, and fast-food restaurantson every corner, are we capable ofconcentrating as well as we usedto?

Before we answer that question,let's take a closer look at concentra-tion, and its sibling, attention.Attention is a global term. It is usedto describe a state in which you areinterested in everything going onaround you. Concentration focusesthat attention on 1 specific thing.

Staying in focus

Attention and concentrationdeveloped in humans as defensemechanisms. Early humans had tobe constantly alert or be eaten. Butit's difficult to keep up a high level ofattention for long periods of timewithout getting stressed out.

Stress is good in small quantities,

but too much stress leads to burnout, accidents, or illness. Think ofyour life today. Stress? That's yourmiddle name, right? Hurry here, hurrythere, with never enough time in theday.

So, with all this stress and a culturethat thrives on short takes, can weconcentrate?

One reason people have troubleconcentrating may be too muchtelevision. When a brain is batteredby so much stimulation, it's hard toconcentrate on just 1 thing. Someexperts have pointed out that achild's attention span is now about7 minutes — the length of time aprogram runs before a commercialbreak. In Europe, by contrast,attention spans seem to be longer.Perhaps that is because there are

Ability to Concentrate Isn't What ItUsed to Be

longer gaps between commercials.

A concentration tune-up

To help tune up your concentration skills, practice these tips:

Cut back on the amount of television you watch, or your children watch.

Get enough sleep. The CDC recommends 7 hours to 9 hours of sleep forteens and adults, 10 hours to 11 hours for school kids, and even more forpreschoolers and toddlers.

Avoid drinks that contain stimulants. Although caffeine or nicotine can giveyou a quick boost, it lasts only a short time.

Pay attention to what you eat. A high-fat meal can leave you feeling sluggish.This is not because the body needs the extra blood to help digest the food.Research has shown that you feel sleepy after eating a meal high in fat orrefined sugar because these foods change the makeup of the amino acidsentering the brain. Try to stay calm and relaxed. Take a short break of a fewseconds to a minute every hour or so at work to break the tension cycle.Just taking a moment to breathe deeply and slowly can help you re-centeryourself.


Anatomy of the biliary system

The biliary system consists of theorgans and ducts (bile ducts,gallbladder, and associatedstructures) that are involved in theproduction and transportation ofbile.

The transportation of bile followsthis sequence:

When the liver cells secrete bile, it iscollected by a system of ducts thatflow from the liver through the rightand left hepatic ducts.

These ducts ultimately drain into thecommon hepatic duct.

The common hepatic duct thenjoins with the cystic duct from thegallbladder to form the commonbile duct, which runs from the liver

to the duodenum (the first sectionof the small intestine).

However, not all bile runs directlyinto the duodenum. About 50percent of the bile produced by theliver is first stored in the gallbladder,a pear-shaped organ locateddirectly below the liver.

Then, when food is eaten, thegallbladder contracts and releasesstored bile into the duodenum tohelp break down the fats.

Functions of the biliary system

The biliary system's main functionincludes the following:

To drain waste products from theliver into the duodenum

To help in digestion with the

The Biliary System: Anatomy andFunctions

controlled release of bile

Bile is the greenish-yellow fluid(consisting of waste products,cholesterol, and bile salts) that issecreted by the liver cells to performtwo primary functions:

To carry away waste

To break down fats during digestion

Bile salt is the actual componentwhich helps break down andabsorb fats. Bile, which is excretedfrom the body in the form of feces,is what gives feces its dark browncolor.


The trouble with dieting, I hearmany women say, "is that ittakes too long. If I want to look

good for my anniversary next month,I should've started losing weightway back in February. Now that I'mfinally focused, it's too late." Well,yes and no. Taking the long-termapproach to weight loss is wisebecause it means you'll lose poundsslowly and steadily -- making it morelikely that you'll keep them off. Butthere are ways to rev up yourmetabolism so you burn caloriesand lose weight more quickly.Check out my favorite no-fail jumpstarts.

Watch Your Fluids

1. Drink green tea. Get this: When arecent study compared themetabolic effect of green tea (inextract) with that of a placebo,researchers found that the green-teadrinkers burned about 70 additionalcalories in a 24-hour period. If youcan believe it, those 70 calories aday add up to a total of 7.3 poundsof fat a year! It's not magic, it'sscience: Researchers believe the

difference is caused by metabolism-enhancing antioxidants known ascatechins, which are found in greentea.

2. Avoid calories in a glass.Scientists now know that the bodydoes not register liquid calories inthe same way it does solid calories.Drinking a grande caffe mocha, forinstance, won't make you feelsatiated the way eating a bowl ofpasta will. Which means thatalthough the caffe mocha actuallyhas a greater number of calories thanthe pasta, you're still more likely towant a second cup from Starbucksthan another plate of linguine. Somonitor your intake of juice, soda,coffee drinks and wine. If youconsume one of each of thosebeverages during the day, you'llhave taken in at least 800 extracalories by nighttime — and you'llstill be hungry. (Incidentally, alcoholmay suppress the metabolism of fat,making it tougher for you to burnthose calories.)Start Lifting

3. Buy a set of five-pound weights.

It's a onetime investment you'll neverregret. Here's why: Strength trainingbuilds lean muscle tissue, whichburns more calories — at work or atrest — 24 hours a day, seven days aweek. The more lean muscle youhave, the faster you'll slim down.How do you start strength training?Try some push-ups or a few squatsor lunges. Use your free weights toperform simple biceps curls ortriceps pulls right in your home oroffice. Do these exercises three tofour times per week, and you'll soonsee a rapid improvement in yourphysique.

4. Lose the salt. Sodium contributesto water retention, making you lookand feel bloated. Do you eat toomuch salt? Probably — the dailyvalue suggests no more than 2,400milligrams of sodium each day (orabout one teaspoon), but most ofus are getting more than twice thatamount. So keep an eye on yoursodium intake, and that doesn't justmean ditching the saltshaker. Hiddensources include soups, cannedfoods and drinks (did you know aserving of regular V8 juice has 800

mg of sodium?), salty snacks suchas chips and pretzels and manyprepackaged foods.

Heat Things Up

5. Spice it up. Angelo Tremblay,Ph.D., director of the division ofkinesiology at Laval University, inCanada, found that eating hotpeppers can boost a person's basalmetabolism (the total calories thebody burns at rest). The reason?Capsaicin, a compound found injalapeno and cayenne peppers, mayincrease your body's release ofstress hormones such as adrenaline,which can speed up your metabo-lism and your ability to burn calories.What's more, eating hot peppersmay reduce your appetite, Tremblaysays, helping to curb your cravings.So spice up your stir-fried veggies,eat low-calorie chili or salsa (try themon salads and baked potatoes), andwatch the pounds come off faster.

6. Get some sleep. As funny as itsounds, sleep deprivation may makeyou fat — and not just becauseyou're susceptible to cases of the

How to Lose Weight Faster, But Safely


late-night munchies (although there's that too). Women who get less thanfour hours of sleep per night have a slower metabolism than those whosnooze for a full eight hours, according to researchers at the University ofChicago. So don't skimp on your zzz's, and you'll be rewarded with anextra edge when it comes to shedding pounds quickly.

Move Around

7. Go for an evening walk. Don't get me wrong — exercising at any time isgood for you. But evening activity may be particularly beneficial becausemany people's metabolism slows down toward the end of the day. Thirtyminutes of aerobic activity before dinner increases your metabolic rate andmay keep it elevated for another two or three hours, even after you'vestopped moving. What that means for you: Those dinner calories have lessof a chance to take up permanent residence on your hips.

8. Eat every meal. Listen up: Skipping meals will not make you lose weightfaster. That strategy backfires because your body thinks food is in shortsupply, so it slows your metabolism in order to conserve energy. Over time,the result is that when you do eat — even if you consume the same foodsas always — your body will be slower to use the calories as fuel, thuscreating a backlog of unwanted pounds. If a hectic day makes a sit-downmeal impossible, stash an energy bar or a piece of fruit in your purse orbriefcase -- anything that will keep you from going hungry.

9. Add 20 minutes of exercise per day. If you're on a diet, you're probably

already working out a couple of times a week. (No? Well, you should start!)But whether you exercise or not, you can get a leg up on all those otherweight-loss wannabes by doing a little something extra each day. Take thestairs instead of the elevator; walk to the bus, train, or all the way to theoffice; window-shop with your best friend rather than sit over coffee. Takingthe dog out, gardening and even housecleaning all increase the number ofcalories you expend. You don't have to go for a jog (although that wouldhelp!) to speed up weight loss. Twenty minutes of moderate exercise a daymeans you'll burn approximately 700 calories.

Drink Up!

10. H20, H20, H20. You've heard it before, and you'll hear it again. That'sbecause drinking 64 ounces of water daily is one of the easiest ways tospeed up weight loss. Your body needs water in order to efficientlymetabolize stored fat. When you shortchange your supply, you're likely toslow down that process, meaning it's more difficult for you to burn calories.An easy eight glasses a day (at least!) will keep your system runningsmoothly.

11. Don't go for the gimmicks. At any given time, there are dozens ofweight-loss hypes in the marketplace that claim to have the ability to take off10 pounds in 10 days, or whatever. Desperation can tempt us to tryanything, but you and I both know these schemes don't work. Save yourmoney, but more importantly, save yourself from the emotional pain whenthese gimmicks fail. Be realistic. Jump-start your weight-loss program in waysthat make sense, and not only will you be thinner, you'll be happier too.


Calcium in the arteries of thebreast predicts early buildupof plaque in the heart's

arteries, and may improve riskassessment in many women,especially young women

Routine mammography--widelyrecommended for breast cancerscreening--may also be a useful toolto identify women at risk for heartdisease, potentially allowing forearlier intervention, according to astudy scheduled for presentation atthe American College ofCardiology's 65th Annual ScientificSession.

Data from this study show for thefirst time a link between the amountof calcium in the arteries of thebreast--readily visible on digitalmammography--and the level ofcalcium buildup in the coronary

arteries. Coronary arterial calcifica-tion, or CAC, is considered a veryearly sign of cardiovascular disease.Importantly, the presence of breastarterial calcification also appears tobe an equivalent or stronger riskfactor for CAC than other well-established cardiovascular riskfactors such as high cholesterol,high blood pressure and diabetes.Earlier research had shown a linkbetween breast arterial calcificationand atherosclerotic disease--evenheart attack, stroke and othercardiovascular disease events, butresearchers said these data providea more direct relationship betweenthe extent of calcified plaque in themammary and coronary arteries, aswell as a comparison to standardrisk evaluation.

"Many women, especially youngwomen, don't know the health of

their coronary arteries. Based on ourdata, if a mammogram shows breastarterial calcifications it can be a redflag--an 'aha' moment--that there is astrong possibility she also hasplaque in her coronary arteries," saidHarvey Hecht, M.D., professor at theIcahn School of Medicine anddirector of cardiovascular imaging atMount Sinai St. Luke's hospital, andlead author of the study.All told, 70 percent of the womenwho had evidence of breast arterialcalcification on their mammogramwere also found to have CAC asshown on a noncontrast CT scan ofthe chest. For women under 60years of age with CAC, half also hadbreast arterial calcification--animportant finding as very few wouldbe thinking about or considered forearly signs of heart disease. Therewere even fewer false positivesamong younger patients; research-

ers said that if a younger woman hadbreast arterial calcification, there wasan 83 percent chance she also hadCAC.

Notably, breast arterial calcificationalso appeared to be as strong apredictor for cardiovascular risk asstandard risk scores such as theFramingham Risk Score, whichunderestimates women's risk, andthe 2013 Cholesterol GuidelinesPooled Cohort Equations, whichtends to overestimate risk, Hechtsaid. When researchers added 33asymptomatic women withestablished CAD, breast arterialcalcification was more powerful thanboth risk assessment formulas,which suggests the presence ofsubclinical atherosclerosis may be amore important indicator of heartdisease than other risk factors. "Thisinformation is available on every

Mammograms: Another way toscreen for heart disease?


mammogram, with no additionalcost or radiation exposure, and ourresearch suggests breast arterialcalcification is as good as thestandard risk factor-based estimatefor predicting risk," Hecht said."Using this information would allowat-risk women to be referred forstandard CAC scoring and to beable to start focusing on prevention--perhaps even taking a statin when itcan make the most difference."

Multivariate analysis showed thatearly signs of a buildup of plaque inthe coronary arteries were moststrongly related to breast arterialcalcification. While CAC was abouttwo times as likely with advancingage or high blood pressure, it wasthree times more likely with breastarterial calcification.

"The message is if a woman isgetting a mammogram, look forbreast arterial calcification. It's afreebie and provides criticalinformation that could be lifesavingfor some women," Hecht said,adding he hopes these findings willprompt clinicians, who rarely report

breast arterial calcification, toroutinely report not just thepresence or absence of breastarterial calcifications but also toestimate and note the amount.

"The more breast arterial calcificationa women has, the more likely she isto have calcium in her heart's arteriesas well. If all it requires is to take acloser look at the images, how canwe ignore it?," he said.

A total of 292 women who haddigital mammography andnoncontrast CT scans within oneyear were included in the study. Ofthese, 124, or 42.5 percent, werefound to have evidence of breastarterial calcification. Mammogramswere reviewed by a secondradiologist who was blinded to theCAC results. Women with breastarterial calcification were more likelyto be older, have high bloodpressure and chronic kidneydisease, and less likely smokers.Women with established cardiovas-cular diseases were excluded.Breast arterial calcification wasevaluated on a scale from zero to 12

by increasing severity, and CAC wasmeasured on the CT using avalidated 0-12 severity score. Theoverall accuracy of breast arterialcalcification for the presence ofCAC was 70 percent, and 63percent of those with CAC also hadbreast arterial calcification.

To date, there is no consensus onusing CAC as a screening test,though a very large outcome studyof 39,000 subjects is underway inthe Netherlands. Mammography,however, is widely used andaccepted and, as Hecht said, mayprovide an opportunity to risk stratifyasymptomatic women by breastarterial calcification who might havecalcium in the coronary arteries andordinarily would not have beenreadily considered for cardiovascularscreening. Heart disease is theleading cause of death amongwomen, yet breast cancer is oftenthe most feared. Roughly 37 millionmammograms are performedannually in the U.S. Mammography isrecommended annually for womenover 40 years of age by theAmerican Cancer Society and every

other year for women 50-75 yearsold and women at high risk forbreast cancer by the U.S. PreventiveService Task Force. Digital mammog-raphy is more sensitive to thepresence of calcifications and isnow available in 96 percent ofmammography units in the U.S.

Another intriguing point thatdeserves additional study, accord-ing to the researchers, is that thenature of the atherosclerosis isdifferent in breast arterial calcificationand CAC, making it unclear why oneshould be related to the other.

Hecht stresses that these findingswarrant further evaluation andvalidation in larger studies. Futureprospective trials are needed to seewhat the prognostic significance ofbreast arterial calcification might be.Because the study involved womenwho received both mammographyand CT scan for clinical indications,these women may have been morelikely than the average woman tohave coexisting conditions, althoughHecht said these were unrelated toheart disease.


Patients recovering from heartattacks or other heart troublecould cut their risk of another

heart incident by half if theyincorporate stress management intotheir treatment, according toresearch from Duke Health.

The findings, published March 21,2016 in the American HeartAssociation journal Circulation, arethe result of a randomized clinicaltrial of 151 outpatients with coronaryheart disease who were enrolled incardiac rehabilitation due to heartblockages, chest pain, heart attacksor bypass surgery. They ranged inage from 36 to 84 years old.

About half of the patients partici-pated in three months of traditional

cardiac rehabilitation, whichincluded exercise, a heart-healthydiet and drugs to manage choles-terol and high blood pressure.The other half went to cardiac rehaband also attended weekly, 90-minute stress management groupsthat combined support, cognitivebehavior therapy, muscle relaxationand other techniques to reducestress. Patients were followed for anaverage of three years after rehab.

Thirty-three percent of patients whoreceived only cardiac rehabilitationhad another cardiovascular eventsuch as a heart attack, bypasssurgery, stroke, hospitalization forchest pain or death from any cause.By comparison, 18 percent of thepatients who participated in stress-

management training during theircardiac rehabilitation had subse-quent cardiovascular trouble --about half the rate of the othergroup.

Both sets of patients who went torehab fared better still than recover-ing heart patients who elected notto attend rehab; 47 percent of thisgroup later died or had anothercardiovascular incident, accordingto the article.

Reducing stress may seem like anobvious part of any plan forimproving heart health, said leadauthor James Blumenthal, Ph.D., aclinical psychologist and professorin psychiatry and behavioralsciences at Duke.

"Over the past 20 to 30 years, therehas been an accumulation ofevidence that stress is associatedwith worse health outcomes,"Blumenthal said. "If you ask patientswhat was responsible for their heartattacks, most patients will indicatethat stress was a contributing factor."But stress management is typicallynot part of most cardiac rehabilita-tion programs, he said.

"I think part of the issue is that stressis hard to define, and there's nouniversally accepted way ofmeasuring it or treating it," Blumenthalsaid. "The data we provide indicatethat by reducing stress, patients canimprove clinical outcomes, evenbeyond the benefits that we knowexercise already has on reducingstress and improving cardiovascular

Adding stress management to cardiac rehabcuts new incidents in half

health." For the trial, patients' stresslevels were measured using fivestandard instruments on whichparticipants self-reported their levelsof depression, anxiety, anger andperceived stress. Overall, those whoparticipated in stress managementreported reductions in anxiety,distress and their overall level ofperceived stress.

Both groups that participated incardiac rehabilitation saw similar andsignificant physical improvements intheir cholesterol levels and proteinsthat indicate heart disease-relatedinflammation, as well as theirexercise capacity.

"We have known for some time thatparticipation in a supervisedexercise program is beneficial inpatients with coronary heartdisease," said Alan Hinderliter, M.D.,cardiologist with UNC Health Careand co-investigator on the trial.

"The results of this study suggest thatstress management is also a veryimportant element of a comprehen-sive cardiac rehabilitation program.The intervention was clearly helpfulin reducing stress levels, but weneed additional research to confirmthe benefits of stress management inimproving cardiovascular out-comes."

Although death rates from heartdisease have improved, it remainsthe No. 1 cause of death in the U.S.and is growing worldwide,according to the American HeartAssociation.


www.cphi-istanbul.com

1 - 3 June 2016 Istanbul Congress Center,

ICC, Turkey Country Roundtable Sessions

Join the Roundtable sessions at CPhI

Istanbul for a holistic view of the Middle

Eastern and African Countries.

21x28_en.indd 1 31/03/16 17:45

Documents

Medical Device ASIA, March-April 2016